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ABSTRACT 
 
For many years the number of Clostridium difficile infections (CDI) has steadily risen. This 
common cause of antibiotic-associated diarrhea can have variable clinical presentations ranging 
from mild diarrhea to severe cases complicated by the development of pseudomembranous 
colitis, electrolyte abnormalities, dehydration, sepsis, and even death. The resistant nature of 
the spores produced by the bacteria and the emergence of hypervirulent strains have made 
treatment challenging. Previous studies have demonstrated clinician non-adherence to CDI 
clinical treatment guidelines may result in poor patient outcomes. This evidence-based practice 
project was implemented at a 311 bed academic medical center in the Midwest. The project 
development, implementation, and evaluation was guided by the Iowa Model Revised: 
Evidence-Based Practice to Promote Excellence in Health Care. Pre-post analysis was used to 
determine the effect of clinician utilization of an evidence-based CDI treatment order set on 
clinical cure rate (resolution of diarrhea and no longer requiring treatment for CDI), 30-day 
disease recurrence, and 30-day readmission rates for CDI. Treatment guideline adherence was 
35% in pre-implementation group and 48.9% in post-implementation group (p= 0.113). 
Guideline adherence did not have a statistically significant effect on recurrence rates (12.3% vs 
14.8%, p = 0.425) or clinical cure rates (15.8% vs 23.9%, p = 0.241). The rate of 30-day 
readmission was higher among the guideline treatment adherent group (7% vs 1.1%, p = 
0.078). However, this finding was not statistically significant. Clinician order set utilization 
increased the rate of guideline adherence versus clinicians that did not use the order set in the 
post-implementation group (83.3% vs 43.6%, p = 0.096). Although this is a promising result, the 
small sample size was not adequate enough to demonstrate statistical significance. Further 
studies are needed to determine the impact of clinician treatment guideline adherence on 
patient outcomes.  
Keywords: Clostridium difficile infection, evidence-based practice, adherence, outcomes
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CHAPTER 1 
INTRODUCTION 
Clostridium difficile infections (CDI) are costly, potentially fatal, and becoming 
increasingly more common in the United States. Nearly half a million people in the United 
States were diagnosed with a Clostridium difficile infection in 2011 (Centers for Disease 
Control and Prevention, 2015). Approximately 83,000 of those people developed at least one 
recurrence of CDI, and 29,000 died within 30 days of the initial diagnosis (CDC, 2015). In 1993, 
CDI led to 85,700 hospitalizations in the United States (Agency for Healthcare Research and 
Quality, 2012). In 2009, the number increased to an alarming 336,600 hospitalizations (AHRQ, 
2012). Over this 16 year period, CDI associated hospitalizations increased nearly four-fold 
(AHRQ, 2012). The average cost for a CDI hospital stay in 2009 was $24,400 with an 
aggregate cost of $8.2 billion (AHRQ, 2012; Reveles, Lee, Boyd, & Frei, 2014). Hospital stays 
that involved CDI as a secondary diagnosis were more than twice as long than those with a 
primary diagnosis of CDI (16.0 days versus 6.9 days) and costs were more than three times 
higher respectively ($31,500 versus $10,100) (AHRQ, 2012). Patients with CDI hospitalizations 
in 2009 were also more severely ill. An estimated 9.1% of all CDI hospital cases were fatal 
compared to less than 2% for all other inpatient hospitalizations (AHRQ, 2012). A study in 
Canada demonstrated patients with hospital acquired CDI had an increased median length of 
stay by six days compared to those who did not acquire the infection during their 
hospitalizations (Forster, Taljaard, Oake, Wilson, Roth, van Walraven, 2012). 
The increased incidence and cost of CDI has not gone unnoticed by the United States 
government healthcare agencies, such as the Centers for Medicare and Medicaid Services 
(CMS). Under the Affordable Care Act (ACA), hospitals are incurring financial penalties for 
several hospital acquired conditions (HAC), as well as excessive readmissions for certain 
conditions. CDI will be added to the HAC measure scoring system for FY 2017 (CMS, 2015). It 
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is critical to understand the characteristics of CDI, the associated risks factors, and develop 
strategies to treat, prevent and, control this growing potentially life-threatening and costly 
infection.  
Background 
 Clostridium difficile is an anaerobic, endospore-forming, gram positive rod-shaped 
bacterium found most commonly in soil and other inanimate surfaces, but it can also occur as a 
part of the flora of the human gut (Singh, & Kappar, 2010; Rineh, Kelso, Vatansever, Tegos, & 
Hamblin, 2014). As a pathogen, C. difficile produces toxin A and B which can result in extensive 
microscopic and gross intestinal disease (CDC, 2015). Furthermore, these microorganisms are 
particularly likely to be the cause of antibiotic-associated diarrhea (AAD) and can occur in any 
individual treated with antibiotics in any setting. C. difficile is easily transmitted between persons 
via an oral-fecal route or from an inanimate objects to persons (Rineh et al., 2014). It has been 
estimated CDI accounts for one-fourth of AAD which represents approximately three million 
cases per year (Rineh et al., 2014). Transmission-based precautions are utilized in healthcare 
facilities to reduce the spread of the spores. Unfortunately, donning gloves and gowns may be 
seen as cumbersome and time-consuming leading to poor compliance to such precautions in 
the clinical setting. 
  In C. difficile infections, toxins are present in an individual’s colon and manifests as an 
inflammatory and/or immune response to the pathogen. Individuals infected with C. difficile may 
develop a variety of clinical signs and symptoms ranging from mild diarrhea and abdominal 
cramps to severe presentations involving the development of septicemia (CDC, 2015). In 
addition, other life-threatening complications may include: toxic megacolon, dehydration, 
electrolyte abnormalities, bowel perforation, acute kidney injury, and other forms of organ failure 
(CDC, 2015; Rineh et al., 2014). It has been estimated that 2 to 8% of patients with CDI will 
develop the potentially life-threatening complication, pseudomembranous colitis (van der Wilden 
et al., 2014). Salvage therapies, such as surgical interventions for complicated cases have 
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associated with poor outcomes with mortality ranging from 35 to 80% (Surawicz et al., 2013). 
However, early operative management of this complication has been associated with improved 
survival (Surawicz et al., 2013).  
Persons at risk for CDI include those with antibiotic exposure, gastric acid suppressant 
use, gastrointestinal surgeries, lengthy stays in healthcare settings, a severe underlying illness, 
immunosuppression, and advanced age (CDC, 2015; Barletta, El-Ibiary, Davis, Nguyen, & 
Raney, 2013). CDI are generally treated with antibiotics, such as metronidazole and 
vancomycin. However, treatment has become more challenging with the emergence of 
vancomycin resistance enterococcus (VRE) and the emergence of a more virulent strain of 
Clostridium difficile, type B1, North America Pulsed Field type 1 (NAP1), or PCR ribotype also 
known as B1/NAP/027 (CDC, 2015; Kenneley, 2014; Louie et al., 2011; Cornely, Crook, 
Esposito, Poirier, Somero, & Gorbach, 2012; O’Horo, Jindai, & Safdar, 2014). The strain is 
believed to be more virulent than historical strains due to its binary toxin or ability to produce 
both toxin A and B (CDC, 2015). Recent successful treatment approaches have also included 
fecal microbiota transplantation. Another treatment, fidaxomicin, has also been noted to 
decrease disease recurrence compared to vancomycin (Cornely, et. al, 2012; Louie et al., 2011; 
Lancaster & Matthews, 2012; Scott, 2013). Due to limited treatment options, emphasis must 
also be placed on preventive strategies to reduce CDI. Those efforts include wiser use of 
antibiotics, avoidance or cautious use of gastric acid suppressants, utilization of contact and 
enteric precautions, hand hygiene with soap and water, using dedicated medical equipment 
when possible, and implementation of cleaning and disinfection protocols and policies (CDC, 
2015; Surawicz et al., 2013; Cohen et al., 2010). 
Impact of Health Policy on CDI. In 2001, the Institute of Medicine (IOM) developed 
their landmark report, Crossing the Quality Chasm: A New Health System for the 21st Century, 
in order to address the healthcare challenges the United States was and still is facing. The IOM 
cited several concerns within the healthcare system that prompted change including: 
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inconsistency in care, patient harm, technology advances, failure to translate knowledge into 
practice, changing healthcare needs, and lack of organization and coordination (IOM, 2001). 
The intent of their publication was to improve the delivery of care by fostering innovation (IOM, 
2001). The IOM suggested six aims for improvement, ten rules for redesign, and three 
approaches to change. The six aims included care that is 1) safe; 2) effective; 3) patient-
centered; 4) timely; 5) efficient; and 6) equitable (IOM, 2001). The ten rules for redesign focused 
on the following principles: a continuous healing relationship, customized care based on patient 
needs and values, patient as the source of control, knowledge sharing with freely flowing 
information, decision making based on evidence, safety, transparency, anticipation of needs, 
decreased waste, and cooperation among clinicians (IOM, 2001). The recommended 
approaches included redesigning health professional training, modifying health professional 
regulations and accreditation, and use a liability system to support change while retaining 
accountability (IOM, 2001). 
Fifteen years after the release of the IOM recommendations to improve the health 
system in the United States, we continue to face challenges in delivering efficient, effective, and 
equitable care. In response, the Patient Protection and Affordable Care Act was enacted in 
2010 with the intent to provide affordable, quality healthcare to all Americans (U.S. Department 
of Health and Human Services, 2015.). Under this law, provisions have continued to be 
developed to further improve the quality and efficiency of healthcare delivery. The Hospital 
Readmission Reduction Program (HRRP) was added under the Affordable Care Act in 2012 
(CMS, 2015). Under this program hospitals can incur financial penalties for excessive 
readmissions within 30 days of discharge for specified conditions. Initially those conditions 
included: acute myocardial infarction, heart failure, and pneumonia (CMS, 2015). Despite the 
attempts to improve health delivery, health expenditures in the United States exceeded $2.9 
trillion or $9,255 per capita in 2013 (CDC, 2015). This represented 17.4% of the United States’ 
gross domestic product (GDP) (CDC, 2015). In 2014, the CMS ruled to expand the HRRP to 
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include additional conditions for fiscal year (FY) 2015. Those additional conditions include: 
chronic obstructive pulmonary disease (COPD), elective total hip arthroplasty (THA), and total 
knee arthroplasty (TKA) (CMS, 2015).  
Although CDI is not currently a condition included under HRRP,  this will soon change. 
Under the ACA, the Hospital Acquired Condition (HAC) Reduction Program was developed in 
effort to reduce hospital acquired conditions, such as catheter associated urinary tract infections 
(CAUTI) and central line associated bloodstream infections (CLABSI) (Medicare.gov, 2015). 
Since FY 2015, the Secretary of the Department of Health and Human Services has been 
required to reduce payments to hospitals that perform poorly with regard to HAC prevention 
(Medicare.gov, 2015). Starting in 2016, surgical site infections (colon surgery and abdominal 
hysterectomy) have been added to HAC measures (Medicare.gov, 2015). In 2017, methicillin-
resistant Staphylococcus aureus (MRSA) and Clostridium difficile infection (CDI) will also be 
added to the quality measures under HAC reimbursement policy (Medicare.gov, 2015). The 
addition of CDI to this legislation will present a particular challenge to advanced practice 
providers and other clinicians who, despite their best efforts to rapidly identify and treat 
individuals with this condition, face an evolving pathogen that is becoming more common, more 
dangerous, and more resistant to standard antibiotic treatment.  
Statement of Problem 
Data from the Literature Supporting the Need for the Project 
Despite efforts to improve CDI prevention and treatment strategies, the cases of CDI 
have continued to rise over the last decade. CDI discharges accounted for 5.6 per 1,000 in 2001 
compared to 11.1 per 1,000 discharges in 2010 (Chopra, Neelakanta, Dombecki, Awali, 
Sharma, Kaye, & Patel, 2015). The CDC (2015) reported nearly half a million people in the 
United States developed CDI in 2011. Approximately 29,000 patients died within 30 days of the 
initial diagnosis of CDI (CDC, 2015). Fifteen thousand of those cases were directly attributed to 
CDI (CD, 2015). One study compared CDI readmissions with all-cause readmissions in seven 
CLOSTRIDIUM DIFFICILE INFECTIONS: BEST PRACTICE       6 
 
tertiary care hospitals and found CDI discharges returned back to the healthcare system nearly 
twice as frequently as all-cause discharges (30.1% vs. 14.1%) (Chopra, Neelakanta, Dombecki, 
Awali, Sharma, Kaye, & Patel, 2015). Among the CDI readmission group, 22.2% were admitted 
for any reason and 7.8% were readmitted with the primary diagnosis of CDI (Chopra, 
Neelakanta, Dombecki, Awali, Sharma, Kaye, & Patel, 2015). It was projected that rates of CDI 
hospitalizations would continue to increase between 2011 and 2012 from 12.5 per 1,000 non-
maternal, adult discharges to 12.8 per 1,000 (Steriner, Barrett, & Terrel, 2012). The potential 
fatal and costly complications associated with CDI and reimbursement reductions for hospital 
onset CDI were additional factors supporting the need for the project.  
Data from the clinical agency supporting the need for the project. The clinical 
agency selected for the evidence-based project has had an increase in the cases of CDI for the 
last three consective years. There were 337 cases in 2013, 361 cases in 2014, and 387 cases 
in 2015 (Y. Wung, personal communication, January 21, 2016). See Figure 1.1. Recurrent 
community onset, recurrent hospital onset, and recurrent community onset-healthcare facility 
onset data for 2015 were not available from the clinical agency. 
 
 
CO- community onset; HO- hospital onset; CO-HCFA- community onset-healthcare facility onset; RCO- recurrent 
community onset; RHO- recurrent hospital onset; RCO-HCFA- recurrent community onset-healthcare facility onset 
 
 
Figure 1.1 Cases of Clostridium difficile Infections at Clinical Agency 
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Purpose of the EBP project 
The purpose of this evidence-based practice project was to determine the effect of 
clinician adherence to an evidence-based treatment order set for Clostridium difficile infection 
(CDI) on clinical cure rate (resolution of diarrhea and no longer requiring treatment for CDI), 30-
day disease recurrence, and 30-day readmissions for CDI. 
Significance of the Project 
 CDIs have increased an alarming rate over the last decade. Despite efforts directed at 
both disease prevention and treatment, they continue to be a significant healthcare challenge. 
CDIs have been associated with longer and more costly hospitalizations. Patient clinical courses 
may be complicated by electrolyte abnormalities, renal failure, toxic megacolon, septicemia, and 
even death. The increased incidence and cost of CDI has not gone unnoticed by government 
healthcare agencies, CMS. Under the ACA, hospitals are incurring financial penalties for 
hospital acquired conditions. CDI will be added to the HAC measure scoring system for FY 
2017. Clinicians and healthcare systems have an opportunity to improve both prevention and 
treatment strategies to combat this potentially fatal and costly problem. Incorporation of an 
evidence-based order set for CDI may be a promising solution in improving clinician adherence 
to treatment guidelines, improving clinical cure rates, and reducing disease recurrence and CDI 
30-day readmissions. 
 
  
CLOSTRIDIUM DIFFICILE INFECTIONS: BEST PRACTICE       8 
 
CHAPTER 2 
THEORETICAL FRAMEWORK AND REVIEW OF LITERATURE 
The theory and evidence-based practice (EBP) model used as the framework to develop 
this evidence-based project were the epidemiological triangle and The Iowa Model Revised: 
Evidence-Based Practice to Promote Excellence in Health Care, respectively. The 
epidemiological triangle provides an understanding of the fundamentals of epidemiology. It is 
essential to understand the basic components of the epidemiological triangle to develop 
effective strategies to diagnose, treat, control, and prevent CDI. An EBP model, such as the 
Iowa Model, offers to guide the user(s) through the process of incorporation of the best 
evidence into clinical practice.  
Theoretical Framework: The Epidemiological Triangle 
Under additions to the ACA, hospitals will begin facing greater financial penalties for 
excessive readmission rates and hospital acquired conditions such as CDI. Clinicians and 
healthcare systems need to develop effective approaches to prevent excessive readmissions 
and hospital acquired conditions to avoid such penalties. Failure to take meaningful action will 
inevitably lead to increased complications, mortality, and potential financial devastation that can 
effect healthcare system viability. CDI is a growing threat that requires effective prevention and 
treatment strategies.   
Description of theoretical framework. The epidemiological triangle is the theoretical 
framework used to illustrate the interaction of the key components of communicable diseases. 
Those components include the infectious agent, the host, and the environment (Bonita, 
Beaglehole, & Kjellström, 2006) (see Figure 2.1). The mechanism by which those components 
interact and the factors that determine disease and infection development are explained by the 
theoretical framework.  
 The first part of the epidemiological triangle is the infectious agent or a microorganism 
that is capable of causing disease or infection. Infection is the state in which an infectious agent 
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enters the host, develops, multiples, and causes the host to develop an inflammatory response 
to the pathogen. The likelihood a microorganism will cause infection within a host is known as 
its pathogenicity. The degree of disease severity caused by the pathogen is known as virulence. 
Pathogens can be carried through the environment through a variety of reservoirs, including 
humans, animals, and inanimate surfaces, which become the source by which the host initially 
acquires the pathogen from the environment. In infectious disease epidemiology, a carrier is a 
person or animal that has the pathogen, but is clinically asymptomatic. These carriers, 
potentially health care providers or visitors, often become important sources of health care 
associated infections (Bonita, Beaglehole, & Kjellström, 2006). 
 The second component of the epidemiological triangle is the environment. This 
component includes transmission or the mode in which the agent is transferred to the host. 
There two main modes of transmission: direct and indirect. Direct transmission is the immediate 
transfer of the infectious agent from an infected host or reservoir to a host. Direct transmission 
may include kissing, touching, sexual intercourse, childbirth, medical instrumentation, coughing, 
sneezing, blood transfusion, or placental transfer. Indirect transmission is categorized as 
vehicle-borne, vector-borne, or airborne. Vehicle-borne transmission may include contaminated 
food or water, towels, or equipment. Vector-borne transmission can occur by way of insects or 
animals. Airborne transmission (long distances) can occur through dust and droplets. Parenteral 
transmission occurs by injection with contaminated needles (Bonita, Beaglehole, & Kjellström, 
2006). 
 The third component of the triangle is the host or the person or animal that is suitable for 
the infectious agent to multiple. The points of entry into the host may be the skin, mucous 
membranes, the respiratory tract, and gastrointestinal tract. The host response to the infectious 
agent may range from clinically asymptomatic to severe illness or death. The environment is a 
crucial element to the development of communicable diseases. Several environmental factors 
such as sanitation, temperature, air quality and water quality can affect any component of the 
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epidemiological triangle (Bonita, Beaglehole, & Kjellström, 2006). Hospitals and other health 
care facilities provide care for patients with a variety of infectious diseases and various states 
immunocompetence, and health care providers and visitors can serve as potential carriers of a 
multitude of pathogens that can be transferred to those patients and cause infection. Medical 
treatments and devices also pose a risk to patients. Medical devices, such as, indwelling urinary 
catheters and central venous catheters are potential portals for infections. Additionally, certain 
medications are capable of immunosuppression or disruption of human normal flora. 
Appropriate and mindful use of invasive, indwelling medical devices, wise medication 
prescribing practices, and utilization of precautions to reduce pathogenic transmission are 
fundamental aspects of preventing hospital acquired infections.  
 
 
Figure 2.1 The Epidemiological Triangle 
 
 
Application of theoretical framework to EBP project. Clostridium difficile is a spore-
forming bacterium that is spread by indirect transmission or more specifically by an oral-fecal 
route. Disruption of normal gut microbiota from antibiotic use and direct ingestion of the spores 
are the two modes by which CDI develops. Inanimate objects or fomites such as commodes, 
faucets, and medical equipment can contain spores on their surface and can be transferred 
from the hands of others that have been in contact with contaminated surfaces. Furthermore, 
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the spores can persist on inanimate surfaces for more than 12 months and have demonstrated 
resistance to many disinfectants (Rineh et al., 2014). A peptidoglycan cortex and several layers 
of a protein coating allow the spores to survive in harsh environmental conditions, including 
some disinfectant methods (Rineh et al., 2014). Although the pathogenesis of CDI is not fully 
understood, certain mechanisms have been identified as key factors in the immune and 
inflammatory responses the bacteria elicits from the host.  
C. difficile pathogenecity is reliant upon the effect of at least one of two major toxins, A 
and B. Although several strains have been identified, about 10 % account for a virulent strain 
known as B1/NAP/027. This strain has been noted to produce high levels of both toxins A and B 
(Rineh et al., 2014). This characteristic has made development of an effective treatment 
challenging. The hypervirulent toxin B has demonstrated broader tropism and cytotoxicity in vivo 
and is more hydrophobic at higher pH levels compared to historical strains. These factors permit 
a more rapid cell entry and the ability to cause a more severe form of illness (Rineh et al., 
2014). Binary toxins are then capable of triggering microtubule protrusions in the gastrointestinal 
epithelial cells and lead to colonization (Rineh et al., 2014). The binary toxins have two main 
mechanisms of action. The first mechanism is the enzymatic action of glucosyltransferases that 
lead to disruption of the cytoskeleton and tight junctions, cell rounding, detachment from the cell 
membrane, and cell death (Rineh et al., 2014). Detachment from the cell membrane in the 
intestinal wall causes the formation of a pseudomembrane between the detached layer and the 
basement membrane, which becomes the primary site for C. difficile biofilm formation. The 
second mechanism involves triggering pro inflammatory mediators and cytokines that causes 
injury by disrupting the protective barrier of the intestinal epithelial lining causing cellular death 
(Rineh et al., 2014; Peniche et al., 2013; Barriò et al., 2014). 
Bile salts have been also identified as one of the important determinants in spore 
germination and inhibition (Rineh et al, 2014; Peniche, Savidge, & Dann, 2013; Barriò et al., 
2014). Primary bile salts (i.e. cholate and taurocholate) have been noted to be stimulators of 
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spore germination while secondary bile salts (i.e. deoxycholate and chenodeoxycholate) have 
been found to inhibit germination and spore growth (Rineh et al, 2014; Peniche, Savidge, & 
Dann, 2013).  
Collectively these responses initiate fluid accumulation, edema, increased mucosal 
permeability, mast cell degradation, epithelial cell death, and changes in neutrophil recruitment 
(Barriò et al., 2014). Complications, such as megacolon, electrolyte derangements, and 
septicemia can then ensue. 
 The two main antibiotics used to treat CDI include vancomycin and metronidazole. 
Vancomycin, a glycopeptide, inhibits cell wall synthesis. Metronidazole, a nitroimidazole, causes 
loss of helical DNA structure by breaking the DNA strand and inhibiting protein synthesis 
leading to cell death. Although they can reduce the number of viable C. difficile bacteria, they do 
not have the capability to inhibit toxin and spore formation.  Eradication of spores in feces has 
proven difficult and their presence has been implicated in 20 to 25% of recurrent cases of CDI 
after treatment (Rineh et al., 2014). Fidaxomicin, a macrocylic antibiotic, has been noted to 
reduce disease recurrence up to 45% (Rineh et al., 2014). The mechanism of action is 
bactericidal, as it inhibits protein synthesis and causes cell death. It additionally has minimal 
systemic absorption with high fecal concentrations (Lexicomp, 2015). However, current 
treatment with fidaxomicin is cost prohibitive (Scott, 2013).  Development of novel therapies 
aimed directed at spore and toxin development and proliferation is fundamental. Until more 
effective treatments are developed, focus on prevention and control strategies will be crucial to 
reduce the growing number of CDI cases. Although this EBP project specifically addresses 
treatment of CDI it will be used in conjunction with prevention and control measures that are 
currently being utilized. Identification of risk factors and minimizing modifiable risks factors will 
also prove to be important clinician considerations. 
It is crucial to have an understanding of the components of the epidemiological triangle 
(the infectious agent, transmission, and the host), as well as their interactions with the 
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environment. Knowledge of each of these components is necessary in order to develop effective 
interventions to prevent, control, and treat infections. Failure to identify the unique 
characteristics of each component will inevitably lead to unsuccessful preventive strategies and 
treatment interventions. CDI is no exception. 
Strengths and limitations of theoretical framework for the EBP project. The strength of 
the framework is its simplicity. It provides the user a fundamental understanding of the 
components of infection and communicable diseases. Additionally, the concept can be easily 
applied to understanding the basic components of a multitude of infectious diseases. The 
epidemiological triangle provides a simple framework for understanding the components of C. 
difficile pathogenicity, effect on the host, its transmission, and how it replicates. 
Despite the clear and concise nature of the epidemiological triangle, it is not specific to 
one infection or disease. While this can be a potential strength of the framework, it could also 
serve as a limitation as it provides little guidance in terms of understanding the specific 
pathogenesis, effective treatments, and potential sequelae of untreated infections. Each 
infectious agent, transmission process, host, and environment is unique. Therefore, 
interventions directed at the components of the epidemiological triangle need to be specific to 
the uniqueness of the infection causing pathogen(s).  
EBP Model of Implementation 
Under the ACA, hospitals are being held accountable for excessive readmissions and 
hospital acquired conditions. Failure of hospital systems to respond appropriately to the 
changes under the ACA could potentially lead to financial instability and threaten organizational 
viability. In 2017, CDI will be among the hospital acquired conditions for which hospitals will 
incur financial penalties. With the rates of CDI more the doubling over the last decade, hospitals 
need to begin developing strategies aimed at prevention and treatment. Clinicians need to find, 
critique, synthesis, and apply best evidence to current practices in CDI prevention and 
treatment. The process continues with implementation of practice changes and evaluation. 
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Finding and evaluating research and new evidence is constantly evolving. It is essential to 
search, evaluate, and apply best evidence to current practices to provide effective and efficient 
care. The Iowa Model Revised: Evidence-Based Practice to Promote Excellence in Health Care 
reflects the dynamic nature of healthcare and can be instrumental in incorporation best 
evidence into practice (Buckwalter et al., 2015). 
Description of the EBP Model and Application to EBP Project 
The Iowa Model of Research-Based Practice to Promote Quality Care was developed in 
1994 by Linda Titler and colleagues and first implemented at the University of Iowa Hospitals 
and Clinics to guide nurses and other healthcare professionals to utilize research findings to 
improve patient care (Titler et al., 2001). The initial version was an algorithm based upon 
identification of triggers to improve clinical practice through research utilization. Triggers were 
categorized as either problem focused or knowledge focused. The problem focused triggers 
included risk management data, quality assessment, quality improvement, identification of a 
clinical problem, total quality management or continuous quality improvement (Titler et al., 
2001). Knowledge focused triggers included national agencies or national organizational 
standards and guidelines, philosophies of care, questions from institutional standards 
committee, and new information in the literature. After a trigger was identified the relevant 
research was assembled, critiqued, and evaluated for practice. If sufficient research existed, 
outcomes to be achieved would be established. A nursing or multidisciplinary practice would be 
developed, and implemented as a practice change on a pilot. An evaluation process would 
follow examining the outcomes. Modifications to the practice change or intervention were made 
if necessary. The change would be implemented into practice if it was deemed appropriate for 
adoption. Outcomes would continue to be monitored after adoption into practice. The results 
would then be disseminated to patient and family, staff, and fiscal department. The utility of the 
original model was well demonstrated as evidenced by the numerous requests for use in 
publications, clinical research programs, clinical practice, and academic courses (Titler et al., 
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2001). The authors of the model were also awarded the Sigma Theta Tau International 
Research Award in 1997 (Titler et al., 2001). Several helpful components of the model were 
noted to be helpful including: the ease of use, decision making points, emphasis on pilot testing, 
and evaluation of change (Titler et al., 2001).  
Despite the acceptance of the original model, changes in healthcare and user feedback 
prompted revisions. The revised model, released in 2001, included the addition of feedback 
loops to illustrate the ongoing process of research utilization, new terminology, and more 
decision points (Titler et al., 2001). Healthcare system changes, such as incentives for 
research-based practice, increased market competiveness, and the need for efficient and cost 
effective practices also incited model revisions (Titler et al., 2001). One of the fundamental 
changes of the original model was a name change to The Iowa Model of Evidence-Based 
Practice to Promote Quality Care. The name change reflected the evolution of utilization of 
research based to evidence-based practice (Titler et al., 2001). The term evidence-based 
practice was more reflective of nursing practice as it incorporated research based information, 
clinical expertise, and patient preferences (Schmidt & Brown, p. 4, 2015). Research refers to the 
systematic search for new knowledge. Although research is utilized in the nursing profession, it 
does not reflect or include the aspects of clinical expertise and patient preferences. In the 
revised model, process improvement data, internal/external benchmarking data, and financial 
data were added under the problem focused triggers (Titler et al., 2001). The addition of new 
research or other literature was included under knowledge focused triggers (Titler et al., 2001). 
Determining if the topic was a priority for the organization was an action step added beneath the 
triggers on the algorithm. The first feedback loop was included after this decision point. If the 
topic was not deemed an organizational priority then the algorithm directed the user back to the 
triggers. If the topic was determined to be a priority then the next action step was to assemble a 
team. The team assembles, critiques, and synthesizes relevant research and other literature. If 
sufficient research supports a change, the practice change was piloted. This involved selecting 
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outcomes to achieve, collecting baseline data, designing evidence-based guidelines, 
implementation of the change, evaluation of the process and outcomes, and any necessary 
modifications. If sufficient research did not support a change then a feedback loop directed the 
user to seek other types of evidence including: case reports, expert opinion, scientific principles, 
and theory. An additional choice for this feedback loop was to conduct new research. After 
considering other sources of evidence or conducting new research the feedback loop directs the 
user to pilot the practice change. After the practice change was piloted, a decision point calls for 
the user(s) to determine if the change was appropriate for adoption into practice. If the change 
was adopted then monitoring and analysis of structure, process, and outcome data was 
conducted. The following action step calls for dissemination then continued back to the 
beginning of the algorithm to problem- and knowledge-based triggers. If a change is piloted but 
not appropriate to adopt into practice then the feedback loop directs the user to continue to 
evaluate the quality of care and new knowledge and then return again to the beginning of the 
algorithm. This incorporation of the feedback loops and actions steps reflected the dynamic and 
cyclic nature of clinical inquiry, searching for evidence, appraisal and synthesis of evidence, and 
the process of piloting a practice change, evaluation, adoption, and dissemination (Titler et al., 
2001). 
The model was again revised and renamed The Iowa Model Revised: Evidence-Based 
Practice to Promote Excellence in Health Care. The finalized version was under review at the 
time of this project (Buckwalter et al., 2015).The first step in the latest revised version is to 
identify triggering issues or opportunities. These include: 1) clinical and patient identified issues; 
2) organization, state, and national initiatives; 3) data/new evidence; 4) accrediting organization 
requirements/regulations; and 5) philosophy of care. The rise in CDI prevalence, evidence of 
poor outcomes associated with guideline discordant treatment, and changes in penalties for 
hospital acquired conditions were the triggering issues that prompted this project. 
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The second step is to state the question or purpose. For this project, the purpose was to 
determine the effect of clinician adherence to an evidence-based order set for CDI treatment on 
clinical cure rates, 30-day disease recurrence, and 30-day readmissions for CDI. 
 The third step or the first decision point is to determine if the topic is a priority. The topic 
of CDI treatment and adherence to current guidelines was determined to be an organizational 
priority as it would potentially improve clinical cure rates, as well as reduce disease recurrence 
and readmissions for CDI. As a result patient outcomes would potentially improve and the 
hospital could potentially avoid costly financial penalties for hospital acquired CDI and 
readmissions. After several meetings and presentations, a multidisciplinary group of 
stakeholders determined the project was an organizational priority. If the topic was not 
considered a priority, the feedback loop would direct the user to consider other triggers. Since 
the topic was determined to be an organizational priority, the next fourth step was the 
development of a team. For this EBP project, the team consisted of a nurse practitioner/nursing 
doctoral student, a gastroenterologist, an internist, and clinical pharmacist. 
 The fifth step was to assemble, appraise, and synthesize the body of evidence. This 
involved conducting a systematic search followed by weighing quality, quantity, consistency, 
and risk. Since sufficient evidence was identified by the user, a practice change was designed 
and piloted as the sixth step in the model. The seventh step was designing and piloting the 
practice change and included: 1) engaging patients and verifying preferences; 2) considering 
resources, constraints, and approval; 3) developing a localized protocol; 4) creating an 
evaluation plan; 5) collecting baseline data; 6) developing and implementing the plan; 7) 
preparing clinicians and materials; 8) promoting adoption; and 9) collecting post-pilot data. If 
evidence was found to be insufficient, a feedback loop directs the user to conduct research. 
 In step eight, the user will determine if the change is appropriate for adoption. If it is 
deemed inappropriate, then a feedback loop guides the user to consider alternatives, and then 
redesign the practice change. If the change is determined to be appropriate, the user will move 
CLOSTRIDIUM DIFFICILE INFECTIONS: BEST PRACTICE       18 
 
to step nine or integrate or sustain the practice change. This step includes identifying and 
engaging key personnel, hardwire change into system, monitor key indicators through quality 
improvement, and reinfuse as needed.  
 The next step is dissemination of the results. After this step the user is directed by a 
feedback loop to step one again, identifying trigger issues and opportunities (Buckwalter et al., 
2015). 
Strengths and limitations of the Iowa Model for the EBP project. The strengths of 
the model include the emphasis of the ongoing, dynamic nature of incorporation of best 
evidence into practice, clinical inquiry through identification of problem and knowledge focused 
triggers, determination of organizational priorities, evidence appraisal and synthesis, piloting 
changes prior to adoption into practice, and dissemination of findings. The revised version of the 
model incorporates feedback loops and action steps that reflect the continuum of incorporation 
of best evidence into clinical practice. An additional strength of the model is the revisions are 
responsive and reflective of current changes in health care. 
Limitations of the model may include lack of relevance in an organization or among 
individual users that fail to recognize the importance of clinical inquiry and incorporation of best 
evidence into practice. The model does not address organizations that may lack financial and 
human resources and effective leaders needed to develop multidisciplinary teams to develops 
and implement evidence-based practice changes. However, the most recent version in review 
now prompts the user to consider resources and constraints. 
Literature Search 
Identification of Sources Examined for Relevant Evidence 
The American College of Gastroenterology (ACG) released an online publication The 
Guidelines for Diagnosis, Treatment, and Prevention of Clostridium difficile Infections in 2013. 
The guidelines were developed to provide recommendations for the diagnosis and management 
of CDI and prevention and control strategies. The authors considered it as a supplement to the 
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2010 Society of Hospital Epidemiologists of America (SHEA)/ Infectious Disease Society of 
America (ISDA) and the European Society of Clinical Microbiology and Infectious Diseases 
(ESCMID) guidelines and an evidence-based review. In addition to well outlined 
recommendations, a summary and strength of recommendations was also provided. The 
GRADE system was utilized for evidence appraisal. SHEA/IDSA released a peer reviewed 
clinical practice guideline for the diagnosis, management, and prevention of CDI in 2010. The 
guideline was developed with the intent to serve as a systematic statement to assist healthcare 
providers to make clinical decisions regarding CDI.  
Search engines. A search for additional evidence was conducted using the Cumulative 
Index to Nursing and Allied Health (CINAHL), ProQuest, The Joanna Briggs Search Institute 
(JBI), the Cochrane Library, and Medline/National Center for Biotechnology Information (NCBI). 
A librarian from Valparaiso University was consulted and assisted with the evidence search.  
Keywords. The keywords included medical subject headings (MeSH terms) in addition 
to quotations, Boolean terms, and truncation. The final combination of terms included 
“clostridium difficile” AND manage* OR therap* OR guideline* or treat*. For JBI “clostridium 
difficile” was used. For the Cochrane Library MeSH term “clostridium difficile” and drug therapy 
were used. 
Inclusion and exclusion criteria. Inclusion criteria included: 1) publications from 2010 
to 2015; 2) adult subjects; 3) publications written in English; and 4) scholarly journals. Exclusion 
criteria included: 1) publications prior to 2010; 2) non-adult subjects; 3) animal subjects; 4) non-
scholarly or unpublished articles; 5) non-English articles; and 6) duplicate articles. 
The search of CINAHL using the above combination of terms, inclusion criteria, and 
exclusion criteria yielded 69 articles. The ProQuest database search yielded 66 articles. JBI 
yielded 28, Cochrane Library 4 articles, and Medline 28 articles. After hand searching the 
results, the following were deemed to relevant, non-duplicate articles: 13 of the 69 CINAHL 
articles, 9 or 66 articles from ProQuest, JBI 2 of 28 articles, Cochrane Library 1 of 4 articles, and 
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Medline 3 of 28 articles. The final yield of relevant, non-duplicate articles was 21 (see Table 
2.1). 
 
Table 2.1  
 
Literature Search Strategies 
 
Database Search terms 
 
Limiters Hits Included 
CINAHL “clostridium 
difficile” 
AND manage* 
OR therap* 
OR guideline* 
OR treat* 
2010 to 2015 
English 
All adults 
Scholarly journals 
251 
251 
73 
69  
8 
ProQuest “clostridium 
difficile” 
AND manage* 
OR therap* 
OR guideline* 
OR treat* 
2010 to 2015 
English 
All adults 
Scholarly journals 
133 
133 
66 
66 
7 
JBI “clostridium 
difficile” 
 
2010 to 2015  28 2 
Cochrane “clostridium 
difficile” and 
drug therapy 
 
2010 to 2015 4 1 
Medline “clostridium 
difficile” 
AND manage* 
OR therap* 
OR guideline* 
OR treat* 
2010 to 2015 
English 
Humans 
Add adherence 
OR readmit* 
Clinical journals 
4377 
1870 
1283 
1048 
206 
28 
3 
 
 
Levels of Evidence and Appraisal of Relevant Evidence 
The Melnyk Hierarchy of Evidence (Schmidt & Brown, 2015) was utilized to categorize 
the level of evidence. The final 21 articles included 5 systematic reviews (level I), 4 evidence-
based practice guidelines (level I), 2 randomized control trials (level II), 1 cohort study (level IV), 
3 case control studies (level IV), 2 systematic reviews of descriptive studies (level V), 1 
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descriptive study (level VI), 2 interventional studies (level VI), and 1 observational study (level 
VI) See Table 2.3. 
The articles were appraised using the Critical Appraisal Skills Programme (CASP) which 
addresses three categories: validity, results, and usefulness. CASP offers tools specific to 
reviews, trials, and case control studies. Each tool offers 10 to 11 questions that address each 
of the above categories. Each question has a set of hints that allow the user to answer each 
screening question. After reading and critiquing each article, a numeric rating was given to each 
appraised article using an adapted version of the CASP tool, (Kline, 2015). With the adapted 
version, each screening question has a value of 2 points. A numeric rating of 0 to 7 is poor, 8 to 
14 is fair, and 15 to 22 is excellent (Kline, 2015). CASP does not have a specific tool to appraise 
clinical guidelines. Therefore, a comprehensive tool from www.evidence-based-medicine.co.uk 
was used. The tool was adapted from the St. George’s Health Care Evaluation Unite Appraisal 
Instrument for Clinical Guidelines, the Leicestershire Evidence Based Guidelines Checklist, and 
the Agency for Health Care Policy and Research Guidelines. The guideline evaluation checklist 
is a series of questions that fall under 15 categories that are used to assess validity of clinical 
guidelines. The categories include: 1) responsibility for the guideline; 2) objectives; 3) guideline 
development group; 4) identification and interpretation of evidence; 5) formulation of 
recommendations; 6) likely costs and benefits; 7) peer review; 8) updating; 9) other guidelines; 
10) overall assessment of the development process;11) applicability; 12) clarity; 13) guideline 
dissemination and implementation 14) national guidelines only and 15) monitoring of 
guidelines/clinical audit (www.evidence-based-medicine.co.uk, 2015.). After reading and 
critiquing each clinical guideline, a rating of either poor, fair, good, or excellent was assigned 
based on utilization of this tool. See Table 2.3 for the literature summary. 
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Table 2.2.  
 
Levels of Evidence 
 
Level of Evidence  
 
Type of evidence Number of articles 
I Systematic reviews 
Meta-analysis 
EBP guidelines 
 
5 systematic reviews 
4 EBP guidelines 
II Randomized control trials 2 randomized control trials 
 
III Controlled trials without 
Randomization 
 
0 
IV Cohort studies or 
Case control studies 
 
1 cohort study 
3 case control studies 
V Evidence form systematic 
reviews of descriptive or 
qualitative studies 
 
2 evidence from systematic 
reviews of descriptive studies  
VI Evidence from single 
descriptive or qualitative 
studies 
1 descriptive study 
2 interventional studies 
1 observational study 
 
VII Evidence from the opinion of 
authorities and/or reports of 
expert committees 
 
0 
 
 
Table 2.3 
 
Levels and Appraisal of Relevant Evidence 
 
Citation 
 
Measures Levels of Evidence 
Bagdasarian, Rao, & Malani, 
(2015) 
Review included: diagnosing, 
testing, and treating CDI 
Level I 
15 excellent 
Barletta, El-Ibiary, Davis, 
Nguyen, & Raney, (2013) 
PPI use and duration and 
development 
nosocomial CDI 
Level  IV 
18 excellent 
Brown & Seifert, (2014) Complication rates for 
patients who received 
guideline-concordant therapy 
Level IV 
18 excellent 
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and guideline-discordant 
therapy 
 
Cohen et al., (2010) Strength of recommend-
ations and quality of evidence 
was graded using an adapted 
tool from the Canadian Task 
Force on Periodic Health 
Examination 
 
Level I 
excellent 
Cornely et. al, (2012) Clinical cure with fidaxomicin 
versus vancomycin 
Level II 
18 excellent 
Jardin, Palmer, Shah, Le, 
Beyda, Jiang, & Garey, 
(2013) 
Use of oral vancomycin for 
severe CDI before and after 
policy implementation 
 
Refractory disease in severe 
CDI before and after policy 
implementation 
 
Level IV 
14 fair 
Jury, Tomas, Kundrapu, 
Sitzlar, & Donskey, (2013) 
Metronidazole for severe CDI 
 
Positive test not acted upon  
 
Time from test to positive test 
results  
 
Time from positive test to 
treatment  
 
Non- adherent treatment 
 
Inappropriate use of empirical 
CDI treatment 
 
Level VI 
10 fair 
Khanna, Aronson, Kammer, 
Baddour, & Pardi, (2012) 
Gastric acid suppression and 
disease 
severity 
Level IV 
16 excellent 
Khanna & Pardi, (2012) CDI treatment effectiveness Level I 14 fair 
Lancaster & Matthews, 
(2012) 
Phase III prospective, 
randomized, double-blind, 
multicenter study compared 
fidaxomicin with oral 
vancomycin for the treatment 
of mild to moderate CDI 
(Louie, et. al) 
 
Level I 
16 excellent 
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End points- clinical cure 
rates, global cure rates, rate 
of recurrence and time of 
diarrhea resolution 
 
 
Phase III randomized, non-
inferiority trial compared 
fidaxomicin to oral 
vancomycin for CDI 
treatment (Crook et. al) 
 
Endpoints- clinical cure, CDI 
recurrence, and global cure 
 
Phase III clinical trial 
evaluating the role of 
concomitant antibiotics with 
fidaxomicin compared to oral 
vancomycin (Mullane, et. al) 
 
Endpoint- does concomitant 
use of antibiotics change 
overall clinical outcomes 
 
Louie et. al, 
(2011) 
Clinical cure rate and global 
cure rate 
Level II 
20 excellent 
McEllistrem, McGraw, Sahud, 
Chan- Tompkins, Goswami, 
& Bhanot, (2014) 
 
Adherence to clinical 
guidelines for CDI treatment 
Level VI 
18 excellent 
Mulherin, Hutchinson, 
Thomas, Hansen, & 
Childress, (2014) 
Concordance of the ATLAS 
scoring system with 
IDSA/SHEA severity staging 
for CDI severity 
 
Sensitivity, specificity, 
positive predictive value, and 
negative predictive value of 
ATLAS scoring system 
 
Clinical characteristics 
associated with CDI severity 
 
Level VI 
16 excellent 
Nelson et. al, (2011) Symptomatic cure,  
bacteriologic cure, and risk of 
relapse 
 
Level I 
16 excellent 
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O’Horo, Jindal, Kunzer, & 
Safdar, (2014) 
Clinical cure of recurrent CDI Level I 
16 excellent 
Ritter & Petri, (2013) Rate of recurrent CDI Level V 
10 fair 
Scott, (2013) Clinical cure rate, recurrence, 
and global cure 
Level V 
18 excellent 
Surawicz et. al, (2013) GRADE system Level I 
excellent 
Van Nispen tot Pannerden, 
Verbon, & Kuipers, 
(2011) 
Treatment options for 
recurrent CDI 
Level V 
12 fair 
Xue, (2014) Efficacy of antibiotic therapy 
for CDI 
Level I 
fair 
Xue, (2014) Efficacy of antimicrobial 
therapy for recurrent CDI 
Level I 
fair 
 
Table 2.3 
 
Levels and Appraisal of Relevant Evidence continued 
 
 
Purpose/ 
Aim 
Sample/ 
Setting/ 
Eligibility Criteria 
 
Design Results/ 
Findings 
Review best 
practice 
evidence for 
diagnosis 
and 
treatment of 
CDI 
116 articles 
 
Studies related to 
CDI diagnosis 
and treatment 
from 1978 to 
2014 
 
Excluded studies- 
non English, 
animal studies 
and studies 
including children 
Systematic 
review 
Best tests included multiple step 
algorithms using PCR or single step 
PCR on liquid stool 
 
Multistep- sensitivity 0.68-1.00 
specificity 
0.92-1.00; Single step-sensitivity 
0.94-0.97 
 
Vancomycin and metronidazole are first 
line therapies for most patients 
 
Treatment failures have been noted 
with metronidazole in severe or 
complicated cases 
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Clinical success rate for severe CDI 
metronidazole 66.3% vancomycin 
78.5% 
 
Newer -therapy fidaxomicin is similar to 
vancomycin but lower recurrence rates 
fidaxomicin 15.4% vancomycin 25.3% 
 
Fecal microbiota transplant response 
rates 83-94% for recurrent CDI 
 
Examine the 
relationship 
between PPI 
use and 
nosocomial  
CDI and 
determine if 
length of use 
increases 
risk of CDI 
n = 201 
(67 with CDI, 
134 matched 
controls) 
 
Two affiliated 
hospitals 
 
Inclusion criteria- 
18 years or older,  
LOS of at least 72 
hours, acquired 
CDI within 48 
hours of 
admission 
 
Exclusion criteria-
community 
acquired CDI 
within 90 days 
 
Matched controls- 
met inclusion  
and exclusion 
criteria,   
matched in a 1:2 
ratio 
Retrospective 
case-control 
Patients with PPI use were more likely 
to develop nosocomial CDI (76% vs 
39%; p <.001) 
 
Patients with longer duration of PPI use 
was a risk factor for nosocomial CDI 
(OR 1.14; 95% CI, 1.02-1.27: p =.018) 
Determine if 
2010 ISDA 
treatment 
guideline 
n = 180 
 
420 bed tertiary 
care referral 
Retrospective 
case-control 
51.7% received guideline concordant 
therapy 
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concordant 
therapy for 
CDI reduces 
the rates of 
compli- 
cations 
county teaching 
hospital 
 
Inclusion criteria- 
18 years or older, 
treated for CDI 
during their 
hospital stay 
Patients receiving guideline concordant 
therapy had  
fewer complications (17.2% vs. 35.6%, 
p = .0007) 
 
Patients with severe and complicated 
CDI received guideline-concordant 
therapy less often than patients with 
mild disease (19.7% vs. 35.3%, and 
81.2% respectively, p <0.001) 
 
Improve the 
diagnosis 
and  
management 
of CDI in 
adult patients  
Literature review 
and analysis  
 
Literature search- 
PubMed, English 
language, 1994 to 
2009, terms 
“Clostridium 
difficile”, 
“epidemiology”, 
“treatment” and 
“infection control” 
 
Reviewed by 
SHEA Board of 
Directors and 
IDSA Standards 
and Practice 
Committee  
Clinical 
guideline  
Mild to moderate CDI- leukocytosis 
15,000 or lower and serum creatinine 
less than 1.5 times premorbid level  
 
Severe CDI- 
leukocytosis greater than 15,000 and 
serum creatinine equal to or greater 
than 1.5 times higher than premorbid 
level 
 
Severe, complicated CDI- 
severe criteria in addition to 
hypotension, shock, ileus, or megacolon 
 
Discontinue inciting antimicrobials as 
soon as possible (A-II) 
 
Initiate empirical therapy as soon as 
severe or complicated CDI is suspected 
(C-III) 
 
Avoid use of  
anti-peristaltic agents if possible (C-III) 
 
Metronidazole 500 mg tid 10-14 days 
for initial mild to moderate CDI (A-I) 
 
Vancomycin 125 mg qid for 10-14 days 
for initial severe CDI (B-I) 
vancomycin 500 mg qid and per rectum 
500 mg in 100 mL normal saline every 6 
hours if ileus is present with or without 
IV metronidazole 500 mg every 8 hours 
for severe, complicated CDI (C-III) 
 
First recurrence mild to moderate CDI, 
same regimen as initial episode (A-II) 
 
Do not use metronidazole beyond first 
recurrence (C-III) 
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Second or third recurrence of CDI, use 
pulse dose or tapered vancomycin (B-
III) 
 
No recommendations regarding 
recurrent CDI in patients who require 
continued antimicrobial therapy for 
underlying infections (C-III) 
 
Compare the 
efficacy and 
safety of 
fidaxomicin 
versus 
vancomycin 
for the 
treatment of 
CDI 
n = 509 (252 
assigned to 
fidaxomicin, 257 
vancomycin) 
 
Multicenter in 
U.S., Canada, 
and Europe 
 
Inclusion criteria- 
CDI, 16 years of 
age or older, no 
more than one 
previous episode 
of CDI in the 3 
months prior 
 
Exclusion criteria- 
negative C. 
difficile toxin, <3 
bowel 
movements in 24 
hours, 
concomitant 
treatment for CDI, 
clinical failures, 
protocol violation, 
cured with < 8 
days treatment 
 
Double-blind, 
randomized, 
non-inferiority 
trial 
Clinical cure with fidaxomicin versus 
vancomycin 
(90.6% vs. 97.5% CI -4.3%) 
 
Non inferiority for clinical cure (87.7% 
vs 86.8%) 
 
receiving concomitant antibiotics for 
other infections cure rate was higher 
with fidaxomicin (90.2% vs. 73.3%; p = 
0.031) 
 
Treatment emergent adverse events 
(7.6% vs. 6.5%) 
Compare 
CDI 
treatment 
patterns and 
patient  
outcomes 
before and 
after  
Implement- 
ation of a 
severity-
n = 256 
144 before policy 
implementation 
112 after 
implementation 
 
Single tertiary 
teaching hospital 
 
Inclusion criteria- 
positive C. difficile 
Cohort study Use of oral vancomycin for severe CDI 
increased significantly following 
implementation of the policy 14% (n= 8) 
to 91% (n = 48) 
 
Refractory disease in patients with 
severe CDI decreased significantly from 
37% to 15% following policy  
implementation 
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based CDI 
treatment 
policy 
stool toxin, age 
18 years of age 
or older 
 
Exclusion criteria- 
received 
antibiotics for CDI 
other than metro-
nidazole or 
vancomycin, 
more than one 
recurrence of CDI 
 
Determine if 
a CDI 
stewardship 
initiative 
would result 
in more 
prompt CDI 
therapy and 
adherence to 
treatment 
recommend-
ations 
Baseline n = 48, 
early intervention 
n = 52, late 
intervention n = 
46 
 
VA center and 
adjacent LTCF 
 
Inclusion and 
exclusion criteria 
not given 
Interventional 
study 
Metronidazole prescribed for severe 
disease- 
baseline vs. early intervention vs. later 
intervention 
6% vs. 0%  
(p =0.03) vs. 0% (p = 1.00) 
Positive test not acted upon 
5% vs. 0%  
(p = .02) vs. 0% (p = .06)  
 
Time from test to positive results 
median hours 
23 vs. 13  
(p = .002) vs. 12 (p = .003) 
 
Time from positive test to treatment 
median hours 
4 vs. 1  
(p = .007) vs. 1 (p = .004) 
 
Non-adherent treatment 
dose or duration 
8% vs. 0%  
(p = .002) vs. 0% (p = .006) 
 
Inappropriate use of empirical CDI 
treatment 
18% vs. 9%  
(p = .07) vs. 2% (p <.0001) 
 
 
Evaluate the 
association 
between acid 
suppression 
and CDI 
outcomes 
n= 385 
county residents 
 
Inclusion criteria- 
CDI inpatient and 
outpatient 
Case control 
study 
36.4% acid suppression (23.4% PPI, 
13.5 % H2 blocker, 0.5% both) 
 
Patients taking acid suppression 
medications were older (69 vs. 56 
years,  
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exclusion criteria- 
recurrent CDI  
 
p = <0.001) and more likely to have 
severe disease (34.2% vs. 23.6%, p = 
.03) and severe, complicated disease 
(4.4% vs. 2.6%, p = .006) 
 
Review 
epidemio-
logy, 
traditional 
and novel 
risk factors, 
and 
advance-
ments in 
treatment of 
CDI 
Review of current 
literature 
Systematic 
review 
1991-2002 in Quebec 9.6% CDI 
treatment failure rate with 
metronidazole then rose to 26% in a 
2003-2004 outbreak; Houston study 
22% failure rate 
 
Lack of initial response with 
metronidazole is associated with 
increased mortality 
 
Oral vancomycin is superior to 
metronidazole in patients with severe 
CDI (cure rate 97% vs. 76%) 
 
Metronidazole is recommended in 
patient first or first recurrent CDI. 
Change to oral vancomycin if no 
improvement in 72-96 hours 
 
Fidaxomicin similar response rates to 
oral vancomycin but fewer recurrences  
(15.4% vs. 25.3%, p = .005) 
 
Fidaxomicin had lower recurrence rates 
in hypervirulent strains compared to oral 
vancomycin (7.8% vs. 25.5%, p <.001) 
 
Patients receiving systematic antibiotics 
concurrent with CDI treatment had 
better cure rate with fidaxomicin 
compared to oral vancomycin (90% vs. 
79.4%, p = 0.48) 
 
Overall success rate for fecal microbiota 
transplant is 92% 
 
No RCTs for recurrent disease 
first recurrence in mild to moderate CDI 
oral metronidazole for 14 days was 
recommended 
 
Second recurrence, 6-7 week tapering 
oral vancomycin regimen was 
recommended 
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Rifaximin, IVIG and vaccines are 
alternative treatments 
 
Review 
published 
literature on 
fidaxomicin 
for CDI 
treatment 
Literature search 
of MEDLINE, 
EMBASE, and 
BIOSIS 
1975 to 2011 
Search terms- 
fidaxomicin, 
tiacumicin B, 
PAR-101, OPT-
80, Clostridium, 
diarrhea, and 
pseudo-
membranous 
colitis. 
 
Additional articles 
were obtained 
from reference 
lists of 
publications, 
meeting 
abstracts, and 
correspondence 
with the 
manufacturer 
 
No grading 
method was used 
for evidence 
appraisal 
Systematic 
review 
Louie et. al 
 
Clinical cure rate 92.1% (fidaxomicin) 
vs. 89.9% (vancomycin) (97.5% CI each 
arm, -2.6), p value not given 
 
Global cure rate 74.6% (fidaxomicin) vs. 
64.1% (vancomycin) (p = 0.006) 
 
Rate of recurrence 15.4% (fidaxomicin) 
vs. 25.3% (vancomycin) (95% CI, -16.6 
to -2.9; p = 0.005) 
 
Resolution of diarrhea 58 hours 
(fidaxomicin) vs. 78 hours (vancomycin) 
p value not given 
 
Crook et. al 
 
Clinical cure rate 87.7% (fidaxomicin) 
vs. 86.8% (vancomycin) (1 sided 97.5% 
CI, -4.9) p value not given 
 
rate of recurrence 12.7% (fidaxomicin) 
vs. 26.9% (vancomycin) (97.5% CI, -
21.4 to -6.8; p value <0.001) 
 
Global cure rate 76.6% (fidaxomicin) vs. 
63.4% (vancomycin) (97.5% CI, 5.2-
20.9; p = 0.001) 
 
Mullane et. al 
 
Clinical cure without concomitant 
antibiotics  84.4%% vs. 92.6%% did not 
receive a concomitant antibiotic (95% 
CI, 3.0%-13.9%; p = <0.001) 
 
Global cure rate without concomitant 
antibiotics  74.7% vs. 65.8% (95% CI, 
2.54%-15.4%; p = 0.005) 
 
Clinical cure rate with fidaxomicin with 
concomitant antibiotics 90.0% vs. 
79.4% with vancomycin and 
concomitant antibiotics (95% CI, 0.23%-
20.3%; p -0.004) 
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Global cure rate with concomitant 
antibiotics 72.7% with fidaxomicin vs. 
59.4% with vancomycin (95% CI, 2.1%-
24.1%, p = 0.02) 
 
Compare 
efficacy of 
fidaxomicin 
vs.  
vancomycin 
for CDI 
n= 548 
 
Multicenter 
study 
 
Inclusion criteria- 
16 years of age 
or older, CDI 
 
Exclusion criteria- 
life threatening or 
fulminant CDI, 
toxic megacolon, 
previous 
fidaxomicin 
exposure, history 
of ulcerative 
colitis or Crohn’s 
disease, more 
than one 
recurrence of CDI 
in 3 months 
Prospective 
double blind, 
parallel-group 
trial 
Clinical cure mITT (modified intent to 
treat) 88.2% (fidaxomicin) vs. 85.8% 
(vancomycin) (97.5% CI of -3.1%) p 
value not given 
 
Rate of recurrence mITT 15.4% 
(fidaxomicin) vs. 25.3% (vancomycin) 
(95% CI -16.6 to -2.9; p = 0.005) 
 
Rate of recurrence for non virulent 
strains C. difficile 7.8% (fidaxomicin) vs. 
25.5% (vancomycin) (95% CI, -27.5 to -
7.9, p = <0.001) 
 
Rate of recurrence strain B1/NAP/027 
24.4% (fidaxomicin) vs. 23.6% 
(vancomycin) (p = 0.93) 
 
Global cure mITT 74.6% (fidaxomicin) 
vs. 64.1% (vancomycin) (95% CI, 3.1 to 
17.7, p = 0.006) 
 
Median time to resolution of diarrhea 58 
hours (fidaxomicin) vs. 78 hours 
(vancomycin) 
 
Usefulness 
of a 
computer-
ized decision 
support tree 
for CDI 
treatment 
n= 78 
 
661 bed acute 
tertiary care 
teaching hospital 
 
Inclusion criteria- 
CDI, non- 
pregnant, ages 
18-89 years, 
treatment with 
metronidazole, 
oral vancomycin 
or combination of 
metronidazole 
and oral 
vancomycin 
 
Exclusion criteria- 
history of CDI in 
Retro- 
spective 
observational 
study 
61.5% of patients received CDI 
treatment non adherent to SHEA/IDSA 
2010 guidelines for CDI.  
 
For mild to moderate disease, 85.7% 
received recommended treatment.  
 
For severe disease, no patients (0/43) 
received recommended treatment (p 
<0.01). 17.9% of patients received 
concurrent oral metronidazole and 
vancomycin (not a currently 
recommended therapy) 
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past 1 year, 
antibiotics for CDI 
< 5 days, 
sequential use of 
metronidazole 
and vancomycin, 
receipt of IV 
metronidazole or 
vancomycin 
enemas 
 
Evaluate 
concordance 
of the ATLAS 
scoring 
system with 
IDSA/ 
SHEA 
severity 
staging for 
CDI severity 
n= 64 
 
350 bed 
community 
hospital 
 
Inclusion criteria- 
CDI, age 19 
years of age or 
older 
 
Exclusion criteria- 
pregnancy, other 
sources of intra-
abdominal 
infection, hyper-
sensitivity to 
metronidazole or 
vancomycin, 
treatment with 
oral vancomycin 
or oral or IV 
metronidazole 
within 14 days 
prior to CDI 
diagnosis 
 
Retrospective 
study 
Bivariate analyses showed moderate 
agreement between the ATLAS scoring 
system and SHEA/IDSA severity 
staging for CDI 
 
Sensitivity of ATLAS in predicting CDI 
severity 58.3% to 87.5%; specificity 
67.5% to 87.5% 
 
Investigate 
the efficacy 
of antibiotic 
therapy for 
CDI, deter-
mine the 
most 
effective 
therapy, and 
deter-mine 
the need for 
stopping 
causative 
15 articles 
 
Literature search 
MEDLINE 1966-
2010, EMBASE 
1980-2010, 
Cochrane Central 
Database of 
Controlled Trials, 
and  the 
Cochrane IBD 
Review Group 
Systematic 
review 
Symptomatic cure 
 
No differences were found among 
metronidazole vs. vancomycin  
3 studies, N = 335 (79% vs. 71%; CI 
95% 0.81-1.03; p = 0.14) 
 
Studies also compared bacitracin vs. 
vancomycin; rifaximin vs. vancomycin; 
nitazoxanide vs. vancomycin; fusidic 
acid vs. vancomycin; teicoplanin vs. 
vancomycin 
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anti-biotics 
during 
therapy 
Specialized Trials 
Registry 
 
Search terms- 
“pseudomem-
branous colitis 
and randomized 
trial”, “Clostridium 
difficile and 
randomized trial”, 
“antibiotic 
associated 
diarrhea and 
randomized trial” 
 
No statistically significant differences 
were found between them  
 
Bacteriologic cure 
1 study, n= 59 
teicoplanin vs. vancomycin (82% vs. 
45%; RR 1.82; 95% CI1.19-2.78; p = 
0.006) 
 
Two studies, n= 163 
no statistical difference between 
metronidazole and vancomycin 
(45% vs. 53%; RR 0.85; 95% CI 0.62-
1.17; p = 0.33) 
 
No statistically significant difference 
between vancomycin and fusidic acid 
 
Relapse 
 
Two studies, n= 104 
no statistically significant differences 
were noted between bacitracin and 
vancomycin; teicoplanin and 
vancomycin; fusidic acid and 
vancomycin; nitazoxanide and 
vancomycin; metronidazole and 
nitazoxanide; metronidazole and 
metronidazole plus rifampin; 
metronidazole and teicoplanin; 
metronidazole and fusidic acid; 
teicoplanin and fusidic acid 
 
Review of 
literature for 
recurrent 
CDI 
management 
64 articles 
 
Literature search- 
MEDLINE, 
CINAHL, 
EMBASE, and 
the Cochrane 
Database 
 
No publication 
date or language  
restrictions 
search terms- not 
given 
 
Systematic 
review 
Vancomycin  
10 studies, 6 high quality 
 
Initial cure rate 20-100%, sustained 
cure rates 49-100% 
pulsing and tapering doses has weak 
evidence 
 
Vancomycin with metronidazole 
comparator  
3 high quality studies 
 
Using sustained response, vancomycin 
was as efficacious as metronidazole RR 
1.08, 95% CI, 0.85-1.35, p =0.53 
 
Vancomycin with fidaxomicin 
comparator 
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fidaxomicin appeared slightly more 
efficacious 
RR 1.86, 95% CI1.04-3.31, p = 0.04 
 
Evidence supporting the use of 
vancomycin is moderate, dosing and 
duration are variable 
 
Metronidazole 
one study concluded metronidazole was 
non inferior to vancomycin in first 
relapse 
 
two studies favored vancomycin 
 
Review 
current 
literature for 
new 
treatment 
options for 
CDI and 
relapse 
Literature review Narrative 
review 
Metronidazole and vancomycin 
 
Cure rate 90% for metronidazole vs. 
98% for vancomycin) 
 
Fidaxomicin and vancomycin 
 
Crook et. al 
 
Clinical cure rate 87.7% (fidaxomicin) 
vs. 86.8% (vancomycin) (1 sided 97.5% 
CI, -4.9) p value not given 
rate of recurrence 12.7% (fidaxomicin) 
vs. 26.9% (vancomycin) (97.5% CI, -
21.4 to -6.8; p value <0.001) 
 
Global cure rate 76.6% (fidaxomicin) vs. 
63.4% (vancomycin) (97.5% CI, 5.2-
20.9; p = 0.001) 
 
Wenisch et al  
Oral metronidazole, IV metronidazole, 
and vancomycin 
 
IV metronidazole 38.1% mortality, oral 
metronidazole 7.4% mortality, 
vancomycin 9.5% mortality 
 
30 day mortality IV metronidazole RR 
4.3 compared to oral vancomycin (95% 
CI 1.92-10, p <0.001) 
 
Use of  
fidaxomicin 
for CDI 
Review of two 
RCTs 
Review of 
RCTs 
OPT 80-003 trial  
Clinical cure  
mITT 88.2% (fidaxomicin) vs. 85.8% 
(vancomycin) 
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(97.5% CI -3.1) 
 
Recurrence 
mITT 15.4% (fidaxomicin) vs. 25.3% 
(vancomycin) 
 
Global cure rate  
mITT 74.6% (fidaxomicin) vs. 64.1% 
(vancomycin) 
 
OPT-80-004 trial 
 
Clinical cure  
mITT 87.7% (fidaxomicin) vs. 86.8% 
(vancomycin) 
 
Recurrence 
mITT 12.7% (fidaxomicin) vs. 26.9% 
(vancomycin) 
 
Global cure rate  
mITT 76.6% (fidaxomicin) vs. 63.4% 
(vancomycin) 
 
Provide 
recomm-
endations for 
the diagnosis 
and 
management 
of CDI as 
well as 
prevent-ion 
and control 
of outbreaks 
Literature review Clinical 
guideline 
Empiric treatment for suspected CDI 
(strong recommendation, moderate 
quality evidence) 
 
Discontinue inciting antimicrobial agent 
if able (strong recommendation, high 
quality evidence) 
 
Mild to moderate CDI metronidazole 
500 mg tid for 10-14 days (strong 
recommendation, high quality evidence) 
 
Severe CDI vancomycin 125 mg qid for 
10 days (conditional recommendation, 
moderate quality evidence) 
 
Failure to respond to metronidazole in 
5-7 days, consider switching to 
vancomycin at standard dosing (strong 
recommendation, moderate quality 
evidence)- 
mild to moderate CDI in pregnant 
women or patients with intolerance to 
metronidazole 
vancomycin with standard dosing 
(strong recommendation, high quality 
evidence) 
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CDI in patients with segment of colon 
not able to be reached by oral 
antibiotics (i.e. Hartman’s pouch, 
ileostomy) 
vancomycin via enema added to above 
treatments until condition improves 
(conditional recommendation, low 
quality evidence) 
 
Avoid or limit use of anti peristaltic 
agents (strong recommendation, low 
quality evidence) 
 
Severe, complicated CDI without 
abdominal distention 
vancomycin 125 mg qid plus IV 
metronidazole 500 mg every 8 hours 
(strong recommendation, low quality 
evidence) 
 
Surgical consultation for complicated 
CDI (hypotension requiring 
vasopressors, sepsis, organ 
dysfunction, mental status changes, 
white blood cell count >50,000, lactate 
equal to greater than 5, failure to 
improve with medical therapy after 5 
days (strong recommendation, 
moderate quality evidence) 
 
First recurrence mild to moderate CDI 
same treatment as initial episode 
 
Severe initial recurrence  
use vancomycin 
 
Second recurrence 
pulsed vancomycin (conditional 
recommendation, low quality evidence) 
 
Third recurrence after pulsed 
vancomcyin 
consider fecal microbiota transplant 
(conditional recommendation, moderate 
quality evidence) 
 
Treatment 
options for 
recurrent 
CDI 
Review of 
literature 
Narrative 
review 
First episode mild to moderate CDI 
stop antimicrobials if possible, 
metronidazole 500 mg tid for 10-14 
days or vancomycin 125 mg qid for 10-
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14 days or if unable to take oral 
medications IV metronidazole 500 mg 
every 8 hours for 10-14 days 
consider fidaxomicin 200 mg bid 
 
First episode severe disease 
vancomycin 500 mg qid for 10-14 days 
or if unable to take oral medication IV 
metronidazole 500 mg every 8 hours for 
10-14 days and vancomycin 500 mg qid 
via nasogastric tube or enema 
 
First recurrence similar to first episode 
consider fidaxomicin 200 mg bid or 
rifaximin 200-400 mg bid for 10-14 days 
Saccharomyces boulardii 500 mg for 
21-28 days 
 
Second recurrence mild disease 
vancomycin 125 mg qid for 10-14 days 
with consider tapering after initial 
treatment, fidaxomicin 200 mg bid or 
rifaximin 200-400mg for 10-14 days or  
Saccharomyces boulardii 500 mg for 
21-28 days 
 
Second recurrence, severe disease 
Vancomycin 500 mg qid 10-14 days or 
if not able to take oral medication then 
IV metronidazole 500 every 8 hours 
AND vancomycin 500 mg qid via 
nasogastric tube or enema 
 
Third or more recurrence 
consider fecal microbiota transplant or 
monoclonal antibodies or immune-
globulins 
 
Life threatening CDI 
surgical consultation and consideration 
of colectomy 
 
Best 
evidence 
regarding 
safety and 
efficacy of 
antibiotic 
therapy for 
CDI 
Literature review Clinical 
guideline 
Rate of initial cure 
vancomycin vs. metronidazole (79% vs. 
66%, p = 0.22) 
 
No difference in mean duration of 
diarrhea related to CDI or toxin 
clearance 
vancomycin vs. metronidazole (2.4 to 
3.2 days), (60% vs. 74%, respectively) 
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Only one study concluded statistically 
significant difference of CDI recurrence 
with fidaxomicin and vancomycin (p = 
0.05) 
 
No antimicrobial therapy is superior to 
others for treatment of initial cure for 
mild CDI 
 
Fidaxomicin may cause less recurrence 
than vancomycin 
 
 
Determine 
the best 
evidence 
regarding 
efficacy and 
safety of 
anti-microbial 
therapy for 
recurrent 
CDI 
Literature review Clinical 
guideline 
First recurrence 
same therapy as initial episode 
 
Moderate CDI 
metronidazole 500 mg every 8 hours for 
10-14 days  
 
Severe CDI 
vancomycin 125 mg every 6 hours for 
10-14 days 
 
Second recurrence 
vancomycin course with taper. 125 mg 
every 6 hours for 10-14 days followed 
by 125 mg every 12 hours for 7 days, 
followed by 125 mg every 24 hours for 7 
days, followed by 125 mg every 48-72 
hours for 2-8 weeks 
 
Vancomycin as effective as 
metronidazole (RR = 1.08, 95% CI, 
0.85-1.35, p = 0.53) 
 
Fidaxomicin is slightly more efficacious 
than vancomycin (RR 1.86, 95% CI, 
1.04-3.31, p = 0.04) 
 
Metronidazole is not recommended for 
repeat course given possible 
neurotoxicity 
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Construct the EBP 
Synthesis of Critically Appraised Literature 
The appraised literature is described using categories of disease severity and defined as 
mild to moderate, severe, severe/complicated, and recurrence. The American College of 
Gastroenterology (ACG) defines mild to moderate disease as diarrhea plus any additional signs 
or symptoms not meeting severe or severe, complicated criteria (Surawicz et al., 2013). Severe 
disease is defined as serum albumin <3gm/dL plus a white blood count of ≥15,000 cell/mm or 
abdominal tenderness (Surawicz et al., 2013). Severe, complicated disease is defined as 
admission to intensive care unit for CDI, hypotension with or without required use of 
vasopressors, fever ≥38.5°C, ileus or significant abdominal distention, mental status changes, 
white blood cells ≥ 35,000 cell/mm, serum lactate >2.2 mmol/L, or end organ failure (Surawicz, 
et al., 2013). The SHEA/IDSA guidelines define mild to moderate disease as white blood cell 
count of 15,000 cells/µL or lower with a serum creatinine level less than 1.5 times the premorbid 
level (Cohen et al., 2010). Severe disease is defined as leukocytosis of 15,000 cells/µL or 
higher with a serum creatinine level greater than 1.5 times the premorbid level (Cohen et al., 
2010). Severe, complicated disease includes the criteria for severe disease in addition to 
hypotension, shock, ileus, or megacolon.  
Mild to moderate CDI. The ACG guidelines recommend discontinuation of inciting 
antimicrobials, avoiding or limiting use of anti-peristaltic agents if possible for any severity of 
CDI, and initiation of empiric therapy until the presence of CDI can be confirmed (Surawiz et al., 
2013). The ACG guidelines recommend metronidazole 500 mg orally three times per day for 10 
days (Surawicz et al., 2013). If no clinical improvement is noted within 5 to 7 days, consideration 
should be given to changing to vancomycin 125 mg orally four times per day for 10 days. If a 
patient is intolerant or allergic to metronidazole or if a woman is pregnant or breastfeeding, 
vancomycin with the above standard dosing should be utilized (Surawicz et al.,2013). First 
trimester exposure to metronidazole is not recommended as there is concern it can cross the 
CLOSTRIDIUM DIFFICILE INFECTIONS: BEST PRACTICE       41 
 
placenta. Case reports have described facial anomalies with maternal metronizadole exposures 
(Surawicz et al., 2013). Metronidazole and its active metabolites have been found in breast milk 
and the plasma of breastfeeding infants (Surawicz et al., 2013).  
The SHEA/IDSA offer the same recommendations with exception of the addition giving 
metronidazole 500 mg orally three times up 14 days for mild to moderate disease (Cohen et al., 
2010). The ACG guidelines recommend 10 days for the length of treatment for mild to moderate 
disease (Surawicz et al., 2013). A systematic review conducted by Bagdasarian et al. (2015) 
also recommends metronidazole 500 mg orally three times a day for 10 to 14 days for mild to 
moderate CDI. Metronidazole by intravenous route is not recommended as monotherapy 
(Bagdasarian et al., 2015). A study by Johnson et al. (2014) showed a lower clinical success 
rate for metronidazole versus vancomycin.  
A systematic review by O’Horo et al., 2014 found moderate-strength evidence that 
treatment with either oral vancomycin or oral metronidazole has consistent efficacy for clinical 
cure. A systematic review by Khanna & Pardi (2012) also showed evidence metronidazole has 
similar efficacy to vancomycin as a treatment for mild to moderate CDI. A systematic review by 
Van Nispen tot Pannerden, C.F., Verbon, A., & Kuipers, E.J. (2011) suggested stopping inciting 
antimicrobials, metronidazole 500 mg orally three times per day for 10 to14 days or vancomycin 
125 mg orally four times a day for 10 to14 days or metronidazole 500 mg intravenous three 
times a day if the oral route could not be given. Consideration to monotherapy with fidaxomicin 
200 mg orally twice daily was also suggested.  
Severe CDI. The ACG clinical treatment guidelines recommend use of vancomycin 125 
mg orally four times per day for 10 days (Surawicz et al., 2013). The SHEA/IDSA guidelines 
recommend provide the same recommendation for severe CDI with the course of treatment can 
be between 10 and 14 days (Cohen et al., 2010).  
A retrospective, non-interventional study by Bass et al., 2012 showed no difference in 
clinical cure between monotherapy with oral vancomycin versus combination therapy of oral 
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vancomycin with oral metronidazole (57.1% vs.65.1%, p = 0.49). However, the sample size was 
small (n =78) and several limitations were noted by the investigators. Those included: 
incomplete medical records, potential unaccounted differences in the clinician’s decision to 
prescribe monotherapy versus combination therapy, practice changes over the span of the 
study, and changed therapy within the first 72 hours (Bass et al. (2013).  
In a systematic review by Khanna & Pardi (2012) oral vancomycin was found to be 
superior over metronidazole for clinical cure rate in severe CDI (97% vs. 76%). A systematic 
review by Bagdasarian et al. (2015) found the same results. An additional study found higher 
treatment failure with metronidazole compared to vancomycin (22.4% vs. 14.2%, p = .002). 
A systematic review by Van Nispen tot Pannerden et al (2011) suggested vancomycin 
500 mg orally four times per day for 10-14 days or metronidazole 500 mg intravenous every 8 
hours if oral route is not possible and vancomycin 500 mg four times per day via nasogastric 
tube or enema. If patients have a segment of the colon that cannot be reached by oral 
medication due an ileus or surgical alteration, consideration should be given to adding 
vancomycin enemas to the above therapies (Surawicz et al., 2013). 
Severe, complicated CDI. The ACG guidelines recommend vancomycin 125 mg orally 
four times per day plus intravenous metronidazole 500 mg three times per day in patients with 
severe, complicated CDI without the presence of abdominal distention (Surawicz et al, 2013). In 
cases complicated by an ileus or megacolon and/or significant abdominal distention, it is 
recommended to use vancomycin 500 mg orally four times per day and per rectum 500 mg in 
500 mL of solution four times per time plus intravenous metronidazole 500 mg three times per 
day. Surgical consultation for possible colectomy should be considered in patients presenting 
with hypotension requiring vasopressors, clinical signs of sepsis, organ dysfunction, mental 
status changes, white blood cell count ≥50,000 cell/µL, lactate ≥5 mmol/L, or failure to improve 
with medical therapy after 5 days (Surawicz et al., 2013). The SHEA/IDSA guidelines 
recommend oral vancomycin 500 mg orally four times per day (and per rectum 500 mg in 100 
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mL normal saline every 6 hours if an ileus if present) with or without intravenous metronidazole 
500 mg three times per day for severe CDI (Cohen et al., 2010). Additionally, a colectomy is 
recommended for severely ill patients. Cases with a serum lactate ≥5 mmol/L and a white blood 
cell count ≥50,000 µL have been associated with increased perioperative mortality (Cohen et 
al., 2010).  
A systematic review by Bagdasarian et al (2015) showed oral vancomycin 125 mg is 
non- inferior to higher doses for the treatment of severe CDI. However, expert opinion favors 
higher doses in both severe and severe/complicated disease. The review also showed support 
for the use of rectal vancomycin as an adjunct therapy. The review also revealed treatment 
failures have also been noted in patients that received intravenous metronidazole as 
monotherapy (Bagdasarian et al., 2015).  
Recurrent CDI. After treatment for an initial episode of CDI, the chance of recurrence is 
10 to 20% (McFarland et al., 2009; Surawicz et al., 2013). After one recurrence, the chance of 
developing further recurrences is 40 to 60%. The ACG guidelines recommend using the same 
regimen as the initial episode for the first recurrence of CDI. However, if the first recurrence is a 
severe presentation then vancomycin is recommended. For a second recurrence, a pulsed 
vancomycin regimen should be used. Fecal transplantation should also be considered 
(Surawicz et al., 2013). The SHEA/ISDA guidelines recommend the same management for 
recurrent CDI (Cohen et al., 2010). 
A JBI review (Xue, 2014) suggest the following tapering vancomycin regimen: 125 mg 
every 6 hours for 10 to14 days, 125 mg every 12 hours for 7 days, 125 mg every 24 hours for 7 
days, and 125 mg every 48-72 hours for 2 to 8 weeks. In a systematic review (Bagdasarian et 
al., 2015), pulsed vancomycin was recommended for subsequent recurrent CDI as cited in 
McFarland et al., (2009). Tapering and pulsed courses of vancomycin were associated with 
significantly fewer recurrences (31%; p = .01 and 14.3%; p = .02) (McFarland et al., 2009).  
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A systematic review by Van Nispen tot Pannerden et al. (2011) also recommended 
repeating the same regimen as the first episode of CDI. For a second recurrence of mild 
disease, fidaxomicin or rifaximin or S. boulardii were suggested. However, there is a risk of 
fungemia associated with S. boulardii use in patients with central venous catheters and 
immunosuppressed patients (Van Nispen tot Pannerden et al., 2011). For a second recurrence 
of mild disease, the same systematic review suggested vancomycin 125 mg orally four times 
per day for 10 to 14 days followed by tapering, fidaxomicin 200 mg twice daily for 10 to14 days, 
or rifaximin 200 to 400 mg twice daily for 10 to14 days, or S. boulardii 500 mg twice daily for 21 
to 28 days (Van Nispen tot Pannerden et al., 2011). For a second occurrence with severe 
disease, vancomycin 500 mg orally four times per day for 10 to14 days or metronidazole 500 
mg intravenous (if oral route is not possible) and vancomycin 500 mg four times per day via 
nasogastric tube or enema were recommended according to the systematic review by Van 
Nispen tot Pannerden et al (2011). Additionally, consideration to fecal transplant, monoclonal 
antibodies, or immunoglobulins were recommended for third and subsequent recurrences (Van 
Nispen tot Pannerden et al.,2011). 
Duration of therapy. Although it is a common practice to prescribe treatment for 10 to 
14 days, the ACG guidelines suggests there is no evidence to support the efficacy of extending 
treatment beyond 10 days in mild to moderate cases of CDI (Surawicz et al., 2013). Additionally, 
there is also no evidence to support use of extending CDI treatment beyond 10 days for persons 
on simultaneous antimicrobial therapy for other infections (Surawicz et al., 2013). 
Gastric acid suppression. A case control study by Khanna, Aronson, Kammer, 
Baddour, & Pardi (2012) showed patients on gastric acid suppression therapy were significantly 
older (69 vs. 56, p <.001), more likely to have severe disease (34.2% vs. 23.6%, p = .03), and 
severe, complicated disease (4.4% vs. 2.6%, p =.006) than patients not receiving gastric acid 
suppression therapy. There was no association found between treatment failure or recurrent 
disease development and gastric acid suppression use. After adjusting for age and co-
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morbidities, patients on gastric suppression therapy were not more likely to experience severe 
disease, severe/ complicated disease, treatment failure, or recurrent infection (Khanna et al., 
2012). 
 A retrospective case control study conducted by Barletta, E-Ibiary, Davis, Nguyen, & 
Ramey (2013) showed hospitalized patients who developed CDI were more likely to have been 
on a proton pump inhibitor (PPI) (76% vs. 39%; p <.001) and had a longer duration of therapy 
(median range 5 days [0-20] vs. 0 days [0-11]; p <.001). A longer duration of PPI therapy was 
found to be associated with CDI. In 2012, the Food and Drug Administration’s Adverse 
Reporting System released a warning to the public PPI use may increase the risk of Clostridium 
difficile associated diarrhea (CDAD). The FDA cited most studies demonstrated a 1.4 to 2.75 
higher risk for CDAD for persons using PPIs compared to those that did not use PPIs. However, 
many of the subjects had other risks factors including antibiotic use, older age, and co-morbid 
conditions (Estes, 2012). 
The SHEA/IDSA and ACG guidelines both suggest limiting or avoiding the use of anti-
peristaltic agents as they may obscure symptoms and trigger the development of complicated 
disease. ACG guidelines suggest the use of anti-peristaltic agents in the presence of CDI must 
include concomitant CDI treatment (Surawicz et al., 2013). 
Fidaxomicin.  Fidaxomicin was approved by the FDA for treatment of CDI in 2011. A 
treatment specifically for CDI had not been approved by the FDA for nearly twenty years prior to 
this approval. Studies have showed promise for its use particularly in regards recurrence rates. 
However, cost remains a factor that may be hindering its use. An academic medical center 
pharmacist provided the following retail costs for 10 day treatment: vancomycin 125 mg orally 
four times a day $1392.00, metronidazole 500 mg orally three times per day $37.84,  
and fidaxomicin 200 mg orally twice daily $3,927.12 (T. Shelton, personal communication, June 
30, 2015). 
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A double blind, randomized control trial RCT comparing the safety and efficacy of 
fidaxomicin and vancomycin for the treatment of CDI, which showed non-inferiority of 
fidaxomicin for clinical cure rate (87.7% vs.86.8%). In patients receiving antibiotics for other 
infections cure rate was higher with fidaxomicin (90.2% vs. 73.3%; p = 0.031). Treatment 
emergent adverse events were not significantly different for fidaxomicin and vancomycin (7.6% 
vs. 6.5%) (Cornley et al., 2012). 
 Scott (2013) conducted a review of two RCTs, the OPT 80-003 trial and OPT-80-004 
trial. The OPT 80-003 trial revealed a similar clinical cure rate between fidaxomicin and 
vancomycin mITT 88.2% vs. 85.8%. Recurrence rate was lower in the fidaxomicin group (mITT 
15.4% vs. 25.3%). Global cure rate were also higher among the fidaxomicin group (mITT 74.6%  
vs. 64.1%). In the OPT-80-004 trial results were similar compared fidaxomicin and vancomycin 
including: clinical cure (mITT 87.7% vs. 86.8%), recurrence (mITT 12.7% vs. 26.9%), and global 
cure rate (mITT 76.6% vs. 63.4%).   
 Another RCT conducted by Louie et al. (2011) also the compared the efficacy of 
fidaxomicin and vancomycin in treatment of CDI. The clinical cure rates for fidaxomicin were 
non-inferior (mITT 88.2% vs. 85.8% respectively). Significantly fewer patients in the fidaxomicin 
group developed recurrence (mITT 15.4% vs. 25.3%, p = 0.005). 
 The ACG guideline did not include fidaxomicin as a current treatment recommendation. 
They did state at the time of its FDA approval for CDI treatment in 2011, only 2 RCTs had 
demonstrated non-inferiority to vancomycin. The ACG guideline authors noted several 
limitations to these studies including: neither trial was over 90 days, no differences in minimal 
inhibitory concentrations (MIC) between B1/NAP/027 and non-B1/NAP/027, both have similar 
activity against gram positive stool bacteria, and surveillance testing in the fidaxomicin arm 
already had revealed the evolution of a C. difficile strain with elevated MIC concentration to 
fidaxomicin due to mutation in the RNA polymerase B.  They additionally cite resistance to 
vancomycin in vitro has not been observed, and cost of fidaxomicin is significantly higher than 
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fidaxomicin. They concluded by advising clinicians should consider fidaxomicin use with caution 
until more post marketing clinical trials are conducted (Surawicz et al., 2013).  
 The 2010 SHEA/ISDA did not include any recommendations regarding the use of 
fidaxomicin in CDI. However, it did not receive FDA approval for use in CDI until May 2011. 
Guideline concordant treatment and patient outcomes. A study by McEllistrom et al. 
(2014) demonstrated of 78 treatment cases in a 661 bed acute tertiary care teaching hospital 
examined 78 cases of CDI and the rendered treatment to determine the potential usefulness of 
a computerized decision support pathway to guideline CDI treatment. Sixty-one percent of 
patients received CDI treatment non adherent to SHEA/IDSA 2010 guidelines for CDI. For mild 
to moderate disease, 85.7% received guideline concordant treatment. However, no patients with 
severe disease (0/43) received recommended treatment (p <0.01). Nearly 18 % of patients with 
severe disease received guideline discordant treatment of concurrent oral metronidazole and 
vancomycin.  
 A study by Jardin et al. (2013) examined the treatment patterns and outcomes for severe 
CDI pre- and post- implementation of a severity-based Clostridium difficile infection treatment 
policy. Use of oral vancomycin for severe CDI increased significantly following implementation 
of the policy (14 % to 91%, p <0.0001), and refractory disease in patients with severe CDI 
decreased significantly from 37% to 15% (p = 0.0035) following policy implementation. 
 Another study by Jury et al. (2013) found a Clostridium difficile stewardship initiative 
improved adherence to practice guidelines and improved timeliness of treatment initiation. The 
number of patients prescribed metronidazole for severe disease decreased from 6% to 0. 
Median time from a positive test to treatment was reduced by 10 hours. 23 vs. 13 (p = .002) vs. 
12 (p = .003). 
 A study by Brown & Seifert (2014) found CDI therapy concordant with the 2010 
SHEA/IDSA guidelines had better outcomes.  The 51.7% of patients that received guideline 
concordant therapy developed fewer complications (17.2% vs. 35.6%, p = .0007). Patients with 
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severe and complicated CDI were found to have received guideline-concordant therapy less 
often than patients with mild disease (19.7% vs. 35.3%, and 81.2% respectively, p <0.001). 
A summation of the CDI pharmacological management recommendations based on 
disease severity have been extracted from two major clinical guidelines, the ACG and 
SHEA/IDSA. The recommendations include treatment for mild to moderate disease, severe 
disease, severe/complicated disease, and recurrent disease. Clinical definitions for each 
disease severity are also based on recommendations from those two major clinical guidelines.  
 
Table 2.4  
 
Recommendation for Treatment and Disease Severity Definitions  
 
Disease severity ACG guidelines SHEA/IDSA guidelines 
 
mild to moderate disease mild – presence of diarrhea 
only 
 
moderate- diarrhea with 
other symptoms not meeting 
severe disease criteria 
 
metronidazole 500 mg orally 
three times per day for 10 
days 
 
if unable to take 
metronidazole, vancomycin 
125 mg orally four times per 
day for 10 days 
 
if no clinical improvement is 
noted within 5 to 7 days, 
consideration should be 
given to changing to 
vancomycin 125 mg orally 
four times per day for 10 
days 
 
WBC ≤15,000 OR serum 
creatinine < 1.5 times 
premorbid level 
 
 
metronidazole 500 mg orally 
three times per day for 10 to 
14 days 
 
severe disease serum albumin <3 g/dL and 
one of the following:  
 
WBC ≥15,000 OR 
abdominal tenderness 
WBC ≥15,000 OR serum 
creatinine >1.5 times 
premorbid level 
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vancomycin 125 mg orally 
four times per day for 10 
days 
 
vancomycin 125 mg orally 
four times per day for 10 to 
14 days 
severe/complicated disease intensive care unit admission 
OR 
hypotension with or without 
required use of vasopressors 
OR 
fever ≥38.5° OR 
ileus OR 
megacolon OR 
significant abdominal 
distention 
 OR 
mental status changes OR 
WBC≥35,000 OR 
WBC <2,000 OR 
serum lactate >2.2 mmol/L 
OR 
evidence of end organ failure 
 
vancomycin 500 mg orally 
four times per day AND 
 
metronidazole 500 mg  
intravenous three times per 
day AND 
 
vancomycin 500 mg in 500 
mL of saline per rectum four 
times per time PLUS 
 
consider surgical 
consultation for possible 
colectomy 
 
hypotension, shock, ileus, or 
megacolon 
 
vancomycin 500 mg orally 
four times per day AND 
 
metronidazole 500 mg three 
times per day AND 
 
rectal instillation of 
vancomycin if a complete 
ileus is present 
first recurrence, mild to 
moderate disease 
recurrence- within 8 weeks 
of treatment completion 
 
same regimen as initial 
treatment 
 
same regimen as initial 
treatment 
first recurrence, severe 
disease 
vancomycin 125 mg orally 
four times per day for 10 
days 
 
vancomycin 125 mg orally 
four times per day for 10 to 
14 days 
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second recurrence vancomycin 125 mg orally 
four times per day for 10 
days followed by 
125 mg pulsed every 3 days 
for ten doses 
vancomycin tapered regimen:  
125 mg every 6 hours for 10-
14 days,  
125 mg every 12 hours for 7 
days,  
125 mg every 24 hours for 7 
days, and  
125 mg every 48-72 for 2 to 8 
weeks 
 
≥ 3 recurrences consider fecal microbiota 
transplant 
consider fecal transplant OR 
consider nitazoxamide OR 
intravenous immunoglobulins 
150-400 mg/kg 
 
 
*Discontinuation of inciting antibiotics should be stopped if possible and gastric acid suppression should be stopped 
or limited if possible 
  
  
Answering the Clinical Question 
What is the effect of clinician adherence to an evidence-based Clostridium difficile infection 
(CDI) order set on clinical cure rate (resolution of diarrhea and no longer requiring treatment for 
CDI), 30-day disease recurrence, and 30-day readmission rates for CDI? 
     The EBP recommendations were based upon the ACG and SHEA/IDSA guidelines and 
supplemented with expert opinions. The recommendations drawn from the literature were 
utilized to develop a pharmacological evidence-based order set for CDI treatment. See Table 
2.5. Although the are several other therapies that have been utilized for the treatment of CDI, 
the focus of this project is on pharmacological management supported by the two current major 
guidelines from ACG and SHEA/IDSA. Expert opinions from a gastroenterologist, an internist, 
and a clinical pharmacist were elicited and incorporated into the order set. Fidaxomicin was not 
included in the order set as it is a non-formulary drug at the clinical agency, and current policies 
do not allow inclusion of non-formulary drugs on order sets. See appendix A.  
The development and implementation provided clinicians with an accessible tool that 
defined disease and provided recommended treatment. The primary outcome were to determine 
CLOSTRIDIUM DIFFICILE INFECTIONS: BEST PRACTICE       51 
 
the effects of clinician adherence to an evidence-based treatment order set on clinical cure rate, 
30-day disease recurrence, and 30-day readmissions for CDI.  
 
CHAPTER 3  
IMPLEMENTATION OF PRACTICE CHANGE  
 Hospital systems are currently facing potential financial penalties for hospital acquired 
infections, such as catheter associated urinary tract infections (CAUTI) and central line 
associated blood stream infections (CLABSI) in order to improve patient outcomes and reduce 
healthcare expenditures. In the next few years, CDI will be included in the Center for Medicare 
and Medicaid’s HAC Reduction Program. Therefore, it is crucial to implement evidence-based 
practices to provide the best care for CDI to achieve clinical cure, reduce the development of 
associated complications, and prevent disease recurrence. This is especially important with the 
emergence of hypervirulent strains of C. difficile and increased risk for recurrent disease. 
Implementation of an evidence-based practice order set for the treatment of CDI can be a 
potential solution to improve clinician adherence to current clinical guidelines. Therefore, 
improvement in clinical cure rates, reduction in disease recurrence, reduction in readmission 
rates for CDI, and prevention of associated complications could potentially be achieved. This 
chapter describes the proposed project methods to answer the following the clinical question: 
What is effect of clinician adherence to an evidence-based Clostridium difficile infection  (CDI) 
treatment order set on clinical cure rate (resolution of diarrhea and no longer requiring 
treatment), 30-day disease recurrence, and 30-day readmission rates for CDI? 
Participants and Setting 
 Participants in the retrospective pre-implementation phase of this project included a 
convenience sample of 100 adult, non-critical care inpatients who met the eligibility criteria at a 
Midwestern academic medical center during the 3-month period of time prior to project 
implementation (n = 100). The participants in the prospective post-implementation phase 
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included a convenience sample of 45 adult, non-critical care inpatients (n = 100). Eligibility 
criteria included patients with a stool assay confirmed CDI, age 18 years or older, and inpatient 
status in a non-critical care areas. Exclusion criteria included non-English speaking patients, 
and persons not able to provide informed consent or consent by proxy.  
 The academic medical center is part of a large and comprehensive health care system. 
The health care system is comprised of 18 hospitals, as well as urgent care centers, and 
multiple outpatient facilities throughout a Midwestern state. The combined hospitals have a total 
of 3,098 staffed patient beds and 29,395 team members. Six of those hospitals have achieved 
and maintained Magnet Designation, a national honorary recognition for nursing excellence 
bestowed by the American Nurses Credentialing Center. Fewer than 400 hospitals nationwide 
have achieved this highly regarded designation (IU Health, 2015).  
 The academic medical center is comprised of two not-for-profit hospitals that have a total 
of 1,371 beds and combined admit 55,379 patients annually. The facility selected for the EBP 
project implementation has a 311 bed capacity. The academic medical center has been 
nationally recognized in The U.S. News Best Hospitals for 18 consecutive years. This is a 
national ranking achieved by the top 3% of U.S. hospitals. Additionally, the health care system 
has a partnership with one of the largest, well known, and prestigious medical schools in the 
Midwest (IU Health, 2015). 
 The mission of the healthcare system is to improve the health of our patients and 
community through innovation and excellence in care, education, research and service. The 
proposed evidence-based project is congruent to that mission of excellence (IU Health, 2015). 
Outcomes 
 The primary outcome of interest was clinician adherence to an evidence-based 
treatment order set for CDI treatment. Secondary outcomes of interest included: achievement of 
clinical cure defined as resolution of symptoms and not requiring further treatment for CDI, 30-
day disease recurrence, and 30-day readmission rates for CDI.  
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Intervention and Planning 
The CDI treatment order set was based on two national guidelines from ACG and 
SHEA/IDSA and supplemented with other high level evidence from RCTs and systematic 
reviews. The order set included severity-based pharmacological treatments, as well as clinical 
definitions for each disease severity. The disease severities included mild to moderate, severe, 
severe/complicated, as well as recurrence. The order set was be reviewed by three health care 
professionals (a gastroenterologist, an internist, and a clinical pharmacist) associated with the 
healthcare system prior to implementation. The feedback from the reviewers was incorporated 
into the order set. The finalized order set was presented to the academic medical center 
informatics review board for approval. Prior to implementation, clinicians were provided with 
information about the order set using a multimodal educational approach, including: email 
notifications, newsletter articles, posters, and face-to-face discussions. It was initially planned 
for C. difficile positive stool assays to trigger a computer-based alert and message referring the 
clinician to utilize the CDI order set. Due to time restrictions associated with implementing the 
project and concern for alert fatigue, this was not feasible. Alert fatigue is a phenomenon that 
occurs when healthcare workers’ exposure to numerous alerts, ranging from physiological 
monitoring alarms to drug-drug interactions notifications with computerized physician order 
entry, can lead to desensitization and failure to respond to such alerts over time. This can 
potentially lead to unintended patient harm. Wise utilization of computer-based alerts may help 
to minimize such unintentional consequence of clinicians and other healthcare workers ignoring 
the alerts (Embi & Leonard, 2012). Clinicians and other healthcare workers at the clinical 
agency currently receive computer-based alert for tobacco cessation, infectious disease (i.e. 
VRE, MRSA), behavioral care contracts, narcotic agreement contracts, and NPO status >72 
hours. 
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Recruiting participants 
 After obtaining Institutional Review Board (IRB) approval, retrospective data were 
collected from a convenience sample of 100 previous patients meeting eligibility criteria. These 
data were supplied by the infection prevention team at the project implementation site in a de-
identified form, so the IRB waived the need to obtain informed consent from participants in the 
retrospective sample.  
The prospective sample was recruited using a sentinel event reporting system within the 
electronic health record that identified all positive C. difficile stool assays during the post-
implementation period. The principal investigator or research assistant approached each patient 
meeting inclusion criteria to explain the purpose, potential risk, potential benefit, and procedures 
of the study, and to invite eligible and interested patients to enroll in the study. 
Data Collection 
Retrospective and prospective data included: participant demographic information, 
where the patient was admitted from, nursing unit, primary team, consulting team, risk factors 
for CDI, disease severity, clinician guideline adherence, order set adherence (post-
implementation group only), clinical cure rate, discharge location, 30- day disease recurrence, 
and 30-day readmission rate for CDI. Retrospective data were collected for participants 
admitted between April 2015 and July 2015, and prospective data were collected from 
November 2015 to February 2016. Data for each participant were recorded on hard-copy case 
report forms and promptly entered into a password-protected spread sheet database that was 
only accessible by the principal investigator and faculty advisor. 
Analysis 
The full data analysis plan is described in Table 3.1. Briefly, characteristics of the 
retrospective and prospective samples were analyzed using descriptive statistics (mean and 
standard deviation for age in years, percent in each category for all categorical variables) and 
compared using Student’s t-test for age in years and either the Chi-square test of independence 
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or Fisher’s exact test for categorical variables. The level of significance for comparing these 
sample characteristics was set at 0.05.  
 Retrospective and prospective data were pooled to answer the primary PICOT question 
for this project. The primary project outcomes (i.e. cure rate, 30-day recurrence of CDI, 30-day 
readmission for CDI) were compared between those with complete treatment adherence to 
those with incomplete treatment adherence using either the chi-square test of independence or 
Fisher’s exact test with a level of significance equal to 0.05.  
Table 3.1  
Data Analysis Plan 
Variables Statistical analysis 
Age (years) mean, standard deviation 
t-test for baseline-to-post comparisons 
Sex % male, % female 
Chi-square test for baseline-to-post 
comparisons 
Race % White, % African-American, % American 
Indian or Alaskan Native, % Asian, % Native 
Hawaiian or Pacific Islander, %  Other, % Not 
identified 
Fisher’s exact test for baseline-to-post 
comparisons 
Location prior to admission % clinic, % home, % emergency department,  
% another hospital, % short term 
rehab/extended care facility, % deceased, % 
other 
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Fisher’s exact test for baseline-to-post 
comparisons 
Primary medical team % internal medicine, % bone marrow 
transplant, % general surgery, % transplant 
surgery, %  hepatology, %urology,  
% pulmonary, % plastic surgery,  
% hematology/oncology, % renal transplant 
Fisher’s exact test for baseline-to-post 
comparisons 
Consulting team and effect on clinical cure 
rate, 30-day recurrence, and 30-day 
readmission for CDI 
% infectious disease, % gastroenterology, % 
both 
Fisher’s exact test for baseline-to-post 
comparisons 
Disease severity % mild to moderate, % severe, % 
severe/complicated, % unknown, recurrent 
mild to moderate, % recurrent severe or % 
severe/complicated, % second recurrence, 
third or more recurrence 
Fisher’s exact test for baseline-to-post 
comparisons 
Risk factors for CDI % immunosuppression, % antimicrobial 
therapy, % healthcare facility, 
 % gastric acid suppression, % history of CDI 
Chi-square test for baseline-to-post 
comparisons 
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Clinician adherence to treatment guideline % yes, % no (orders must have been adherent 
to current clinical guidelines) 
Chi-square test for baseline-to-post 
comparisons 
Clinician order set use % yes, % no  
Fisher’s exact test for post-implementation 
analysis 
Over treatment 
Under treatment 
% yes, % no 
%yes, % no 
Chi-square test for baseline-to-post 
comparisons 
Clinical cure prior to discharge (resolution of 
diarrhea and no longer requiring treatment 
for CDI) 
 
% yes, % no 
Chi-square test for baseline-to-post 
comparisons  
30-day readmission for CDI % yes, % no 
Chi-square test for baseline-to-post 
comparisons  
Effect of clinician guideline adherence on 
clinical cure rate 
 
Chi-square test of independence for 
comparison between adherent and non-
adherent groups 
Effect of clinician guideline adherence on 
30-day disease recurrence 
 
Fisher’s exact test 
for comparison between adherent and non-
adherent groups 
Effect of clinician guideline adherence on 
30- day readmissions for CDI 
 
 
Fisher’s exact test for comparison between 
adherent and non-adherent groups 
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Protection of Human Subjects 
 Prior to seeking IRB approval to conduct the study, a required computer-based course 
on protecting human subjects was completed by the PI. IRB approval was received from 
Valparaiso University. The clinical agency IRB policy required students not associated with their 
university affiliate to obtain IRB only from their affiliated university. However, the proposed study 
was presented to the academic center’s nursing research committee. Informed consent was 
obtained from each participant or from a legally authorized representative. If informed consent 
was obtained from a legal representative, a legal documentation stating the right serve as the 
legal representative of the participant was obtained and kept with the informed consent. Once 
data collection began, the patient health information was stored in a locked filing cabinet 
accessible only to the primary investigator. Any computer based records were password 
protected to ensure privacy of the subjects. Due to the number of participants to consent, IRB 
approval was made to include the utilization of research assistants to obtain consent was 
requested and granted.  
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CHAPTER 4 
 
 FINDINGS  
The purpose of this evidence-based project was to determine the effect of adherence to 
an evidence-based CDI treatment order set on clinical cure rates, 30-day disease recurrence, 
and 30-day readmissions for CDI. A computer-based order set for CDI treatment was developed 
and implemented for clinician utilization. The aim was to determine if clinician adherence 
improved patient outcomes. 
Size 
Baseline data were collected from a pre-implementation group consisting of a 
convenience sample of 100 inpatient adults diagnosed with stool assay confirmed CDI at a 
Midwestern academic center from April 2015 to July 2015 (n = 100). Post-implementation data 
was gathered from a convenience sample of 47 (n = 47) at the same academic medical center 
from November 2015 to February 2015. Two patients were still hospitalized at the end of the 
study period and therefore were excluded from the post-implementation group leaving a post-
implementation sample of 45 (n = 45). 
Characteristics 
Age, gender, race, length of stay, location prior to admission, and disease severity did 
not differ significantly between the retrospective and prospective samples. Risk factors for the 
development of CDI were also similar between the pre- and post-implementation groups with 
exception of antimicrobial therapy (60% vs. 77.8%, p = 0.037) and recent healthcare facility stay 
(17% vs. 40%, p = 0.003). See Table 4.1. 
 Twenty-two percent of participants in the retrospective sample experienced clinical cure, 
compared to eight percent in the prospective sample. This difference was not statistically 
significant (p = 0.562). There was also a statistically nonsignificant difference between the 
retrospective and prospective samples with regard to CDI recurrence or CDI re-admissions (p = 
0.425 and 0.096, respectively). 
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 The effect of gastroenterology and infectious disease consultation on outcomes was also 
analyzed. The highest level of adherence was observed when either the gastroenterology or 
infectious disease service was consulted (50%). If neither of these services were consulted, 
adherence was 36.5%. If both of these services were consulted, adherence was only 25%. 
However, these differences were not statistically significant (p = 0.434). There was also not 
enough evidence to conclude that the clinical cure rate was better when consulting 
gastroenterology or infectious disease specialists (p = 0.504). The 30-day recurrence rate was 
21.4% when consulting gastroenterology and 8.3% rate when consulting infectious disease. 
When consulting both, the recurrence rate was 25%, and when consulting neither, the 
recurrence rate was 11.9%. There was not enough evidence to conclude consulting either team 
improved recurrence rates (p = 0.628). There were only five 30 day readmissions for CDI; 
therefore, the effect of consultation could not be answered with any confidence.  
Table 4.1 
Characteristics of Pre- and Post-Implementation Groups 
 
      
Characteristics             Pre-implementation  Post-implementation  p 
              (n = 100)       (n = 45) 
  
 
Age (years) a    54.8 (16.1)   53.2 (16.8)  0.594 
 
Gender (%)b 
  Male     53 (53.0)   25 (55.6)  0.775 
  Female     47 (47.0)   20 (44.4) 
 
Race (%)c           0.824 
  Black     16 (16.0)   8 (17.8)   
  White     82 (82.0)   36 (80.0)   
  Hispanic    1 (1.0)    1 (2.2) 
  Unknown    1 (1.0)    0 (0.0) 
 
Length of stay (days) d   7 (4-19)    1 (6-21)  0.155  
 
 
Admitted from (%)c         0.399 
  Clinic     11 (11.0)   4 (8.9)   
  Home     32 (32.0)   10 (22.2) 
  Emergency department   13 (13.0)   5 (11.1) 
  Other hospital    32 (32.0)   23 (51.1) 
  Short/long term care   3 (3.0)    0 (0.0) 
  Unknown    9 (9.0)    3 (6.7) 
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Risks (%)b 
  Immunosuppression   53 (53.0)   29 (64.4)  0.198 
  Antimicrobial use   60 (60.0)   35 (77.8)  0.037 
  Recent healthcare facility   17 (17.0)   18 (40.0)  0.003 
  Gastric acid suppression   75 (75.0)   36 (80.0)  0.511 
  History of CDI    28 (28.0)   10 (22.2)  0.464 
 
Disease severity (%)c          0.271 
  Mild to moderate   35 (35.0)   22 (48.9)   
  Severe     13 (13.0)   4 (8.9) 
  Severe/complicated   23 (23.0)   11 (24.4) 
  1st recurrence mild to moderate  3 (3.0)    2 (4.4) 
  1st recurrence severe   8 (8.0)    1 (2.2) 
  2nd recurrence    6 (6.0)    0 (0) 
  3rd or more recurrence   12 (12.0)   4 (8.9) 
  Asymptomatic    0 (0.0)    1 (2.2) 
   
aReported as mean (SD), p-value from two-sample t test. 
bReported as count (%), p-value from chi-square test. 
cReported as count (%), p-value from Fisher’s exact test. 
dReported as mean, p-value from Wilcoxon sum test 
  
Clinician characteristics 
Pre- and post-implementation characteristics of the primary and consulting teams were 
similar. See Table 4.2. 
Table 4.2  
 
Pre- and Post-Implementation Clinicians  
   
 
Primary team (%)c         0.657  
  Internal medicine   38 (38.0)   17 (37.8)   
  Bone marrow transplant   7 (7.0)    3 (6.7) 
  General surgery    10 (10.0)   4 (8.9) 
  Transplant surgery   11 (11.0)   6 (13.3)  
  Hepatology    4 (4.0)    5 (11.1) 
  Urology    10 (10.0)   3 (6.7) 
  Pulmonary    1 (1.0)    2 (4.4) 
  Hematology/oncology   11 (11.0)   2 (4.4) 
  Renal transplant    6 (6.0)    3 (6.7) 
  Plastic surgery    2 (2.0)    0 (0.0) 
 
Consultants (%)c          0.705 
  Gastroenterology   19 (19.0)   9 (20.0) 
  Infectious disease   8 (8.0)    4 (8.9) 
  Both     4 (4.0)    0 (0.0) 
  Neither     69 (69.0)   32 (71.1) 
 
aReported as mean (SD), p-value from two-sample t test. 
bReported as count (%), p-value from chi-square test. 
cReported as count (%), p-value from Fisher’s exact test. 
dReported as mean, p-value from Wilcoxon sum test 
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Treatment measures 
A Chi-square test and the Fisher’s exact test were used to determine the effect 
evidence-based guideline treatment order adherence on clinical cure rates, 30-day recurrence 
rates, and 30- day readmissions for CDI in the pre- and post-implementation groups. 
Outcomes 
The overall rate of guideline adherence was 39.3% (pre- vs post-: 35% vs 48.9%, p = 
0.113). When guideline adherence was not met, 17.9% (pre- vs post-: 18 vs 17.8%) was over- 
treatment and 41.4% (pre- vs post-: 45% vs 33.3%) was under treatment. The effect of guideline 
adherence on achievement of clinical cure rate (resolution of diarrhea and no longer requiring 
treatment) was 15.8% adherent group vs 23.9% non-adherent (p = 0.241). The effect of 
guideline adherence on 30-day recurrence rates was 12.3% adherent group vs 14.8% non-
adherent group (p = 0.425).The effect of guideline adherence on 30-day readmission rates was 
7.0% among the guideline adherent group versus 1.1% among the non-adherent group (p = 
0.078).   
Table 4.3 
Treatment Guideline Adherence 
 
 
 
Frequency 
Percent 
Row Percent 
Collective percent 
             
          Adherent          Over treatment          Under treatment        None            Total 
 
Pre-      35                     18                              45                                2                   100 
             24.14                12.41                         31.03                           1.38              68.97 
             35.00                18.00                         45.00                           2.00   
             61.40                 69.23                        75.00                           100.00             
              
Post-     22                     8                                15                                0                   45 
             15.17                5.52                            10.34                          0.00               31.03 
             48.99                17.78                          33.33                          0.00 
             38.60                30.77                          25.00                          0.00 
      
Total     57                     26                               60                                2                   145 
             39.31                17.93                          41.38                           1.38               100.00                
 
 
 
 
 
 
 
 
 
CLOSTRIDIUM DIFFICILE INFECTIONS: BEST PRACTICE       63 
 
Table 4.4 
 
Guideline Adherence Effect on Clinical Cure Rate 
 
 
 
 
 
 
Frequency 
Percent 
Row Percent 
Collective percent 
 
Adherence            Clinical cure 
 
                               Yes            No              Unknown            Not applicable        Total 
 
Yes                          9               47               1                          0                                57 
                                6.21          32.41           0.69                    0.00                           39.31 
                                15.79        82.46           1.75                    0.00  
                                30.00        45.19           25.00                  0.00 
 
No                           21             57                 3                         7                                88 
                               14.48        39.31            2.07                    4.83                            60.69 
                                23.86       64.77            3.41                    7.95 
                                70.00       54.81            75.00                  100.00 
 
Total                        30            104               4                         7                                 145 
                                20.69        71.72           2.76                    4.83                             100.00 
 
 
         
 
 
Table 4.5 
 
Guideline Adherence Effect on 30-day Recurrence Rates 
 
 
 
 
 
 
Frequency 
Percent 
Row Percent 
Collective percent 
 
Adherence                          Recurrence 
 
                                              Yes                  No                 Deceased                  Total 
 
Yes                                       7                       47                  3                                  57 
                                             4.83                  32.41              2.07                            39.31 
                                             12.28                82.46              5.26       
                                             35.00                38.84              75.00 
 
No                                        13                     74                   1                                  88 
                                             8.97                  51.03              0.69                            60.69 
                                             14.77                84.09              1.14                             
                                              65.00               61.16               25.00 
 
Total                                      20                    121                 4                                 145 
                                              13.79               83.45              2.76                            100.00 
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Table 4.6 
 
Guideline Adherence Effect on 30-day Readmission for CDI 
 
 
 
 
 
 
Frequency 
Percent 
Row Percent 
Collective percent 
 
Adherence                         30-day readmission for CDI 
 
                                            Yes                    No                    Total 
 
Yes                                     4                         53                     57 
                                           2.76                    36.55                 39.31 
                                           7.02                    92.98 
                                           80.00                  37.86 
 
No                                      1                          87                      88 
                                           0.69                     60.00                 60.69 
                                           1.14                     98.86                 
                                           20.00                   62.14 
 
Total                                  5                          140                     145 
                                          3.45                      96.55                 100.00 
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CHAPTER 5 
DISCUSSION 
The purpose of this evidence-based project was to determine the effect of clinician 
adherence to Clostridium difficile infection treatment guidelines on clinical cure rates, 30-day 
disease recurrence, and 30-day readmissions for CDI. The following section includes a 
discussion of the findings, applicability of the theoretical and evidence-based practice 
framework, study strengths and weakness, and clinical implications. 
Explanation of findings 
Adherence to the CDI severity-based treatment guidelines did not significantly improve 
clinical cure rates, 30-day recurrence rates, or 30-day readmission rates for CDI. In fact, the 
clinical cure rate and 30-day readmission rates for CDI tended to be worse in those with 
complete guideline adherence. Because these results were not statistically significant, they 
could have occurred due to chance alone. However, these paradoxical findings require further 
investigation to explore factors that could be useful in predicting which patients will benefit from 
guideline adherence and which ones may not. One way to approach this would be to collaborate 
with a nurse scientist and/or biostatistician to develop regression models that can be used to 
explore the effects of various predictors, including interaction effects, on each outcome. While 
this approach is beyond the scope of this project, another approach may be to collaborate with 
clinicians or use clinical experience to identify variables that may have had an impact on the 
outcomes of interest.  
Forty-five of the eighty-five of CDI cases were included in the prospective sample. Forty 
patients were not included for various reasons. Twenty-one patients were discharged prior to 
the investigator being able to obtain IRB required written consent for participation. The principal 
investigator (PI) was at the academic medical center three days a week. Therefore, there were 
several patients discharged prior to the PI returning to the academic medical center resulting in 
missed recruitment opportunities. Two patients were excluded from the study as they were still 
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hospitalized at the time the study ended. Therefore, data on clinical cure, 30-day recurrence, 
and 30-day readmission rates could not be obtained in those two cases. To reduce the number 
of lost recruitment opportunities three research assistants (2 nurse practitioners and 1 
physician) were added after IRB approval was received. Two cases were disease recurrence 
readmissions and were ineligible due to previous recruitment. Ten patients had some degree of 
altered mental status making informed consent unattainable. Two were intensive care patients 
and therefore were excluded due to failure to meet eligibility criteria. Two patients refused 
participation. One patient refused participation citing previous participation in multiple studies 
and several recent hospitalizations. The other patient was not able to fully comprehend the 
purpose of the study and his family declined participation on his behalf. One patient had a 
positive C. difficile stool assay without symptoms and was considered colonized. In the post-
implementation group, 47% of patients that were diagnosed with CDI were not included in the 
study. Patients that were not consented due to altered mental status, may have more severe 
presentations of this disease. On the other hand, some of the patients that were discharged 
prior to being consented may have had shorter length of stays and less severe disease. 
Therefore, the post-implementation sample (n = 45) may not have been a true representation of 
the patients diagnosed with CDI at the clinical agency during the post-implementation period.  
Treatment variability and experience of the prescribers may also have accounted for 
outcome differences. At the academic medical center, residents and fellows begin new rotations 
in July. Post-implementation data were collected after a new group of residents started rotations 
as opposed to the retrospective sample that received care from more experienced medical 
residents and fellows. Therefore, the prospective sample may have received less treatment 
from less experience clinicians.  
There also may have been a greater number of patients with post-discharge follow up 
outside of the academic medical center health care system. Since the clinical agency is a 
tertiary care center it is common for patients to receive post-discharge care at other health care 
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systems. Therefore, there may have been unaccounted for cases of disease recurrence and/or 
readmission for CDI.  
There also may have been confounding factors between the pre- and post-
implementation groups that results in outcome variability. Those factors may have included co-
morbidities, acuity levels, re-admissions to other hospitals, patient noncompliance non-
adherence with treatment, and failure to correctly use appropriate CDI transmission-based 
precautions. Since participants were not randomly assigned to either the “adherent” or “non-
adherent” groups, and these variables were not measured in this project, it cannot be assumed 
or verified that the confounding factors listed above were evenly distributed between participant 
groups.   
An additional explanation for outcome variability may have been in the informatics 
design of the order set. Other computer-based order sets at the clinical agency leave all of the 
order options visible once a treatment option has been selected and initiated. For example, if a 
clinician selected metronidazole 500 mg orally three times a day for ten days under the mild to 
moderate disease recommendations, then all of the other treatment options would no longer be 
visible. If the patient did not respond to the initial treatment with 5 to 7 days or if the patient 
development a higher disease severity from initial presentation it would have been appropriate 
to escalate the treatment. However, those other treatment options would no longer have been 
visible to the clinician without initiating a new CDI order set. With the CDI order set, once a 
treatment option is selected all the other options “drop off” and are no longer visible. Therefore, 
clinicians who used the order set were unable to use the same order set to modify the CDI 
treatment plan. They would have had to initiate a new CDI order set for the patient if the disease 
severity changed, which is not how order sets are traditionally used in the implementation site. 
This may have hindered clinicians escalating treatment in participants who did not respond to 
the initial treatment or for those patients that developed a worsening severity of disease.  
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 The results of this study varied from previous studies examining the effect of guideline 
adherence on patient outcomes that identified a statistically significant positive effect of clinician 
guideline adherence on patient outcomes. One retrospective study at a 420 bed tertiary care 
center examined the effect of treatment variation on the development of CDI related 
complications including recurrence, any surgical procedure to cure CDI, toxic megacolon, and 
30-day mortality (Brown & Seifert, 2014). Length of stay and achievement of clinical cure rates 
were also examined. Only 51.7% of prescribers were followed the 2010 SHEA/IDSA treatment 
guidelines (Brown & Seifert, 2014). The patients who received guideline-adherent treatment had 
fewer complications than those patients who received guideline non-adherent treatment (17.2% 
vs 56.3%, p = <.0012) (Brown & Seifert, 2014). The difference was mainly due to a reduction in 
mortality (5.4% vs 21.8%, p = .0012) and infection recurrence (14% vs 35.6%, p = .007) (Brown 
& Seifert, 2014). Patients who presented with severe and severe complicated disease received 
guideline adherent treatment significantly less often than with mild disease which was consistent 
with the findings of this EBP study (Brown & Seifert, 2014). Study design may account for some 
of the outcome difference. This study was retrospective, had a larger sample (n = 180), included 
intensive care patients, and a more diverse racial composition that may or may not account for 
outcome differences. There were also no cases of CDI related mortality in this study that may 
have impacted outcome differences. The investigators acknowledged that there may have been 
unaccounted for treatment failures as there were no formal follow ups with patients upon 
discharge (Brown & Seifert, 2014).  
 Three identified studies examining the effect of guideline adherent treatment on patient 
outcomes all demonstrated a significant rate of clinician non-adherence which was consistent 
with this study. The three studies had pre-intervention guideline non-adherence rates ranging 
from 51.7% to 89.0% (Brown & Seifert, 2014; Jardin et al., 2013; Mc Ellistrom et al., 2014). 
Another study demonstrated improvement in refractory disease after implementation of a 
severity-based treatment policy (37 % to 15%, p = 0.035) (Jardin, et al., 2013). Again, the 
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sample size was larger (n = 144). Additionally, the outcome difference may have been related to 
the mandatory nature of the treatment policy change. Utilization of the guideline- adherent order 
set in this study was voluntary for clinicians.  
Theoretical framework 
The epidemiological triangle was the theoretical framework used to illustrate the 
interaction of the key components of communicable diseases, in this case Clostridium difficile 
infections. The components as it applied to the study included: Clostridium difficile (the 
infectious agent), patient (the host), and the academic medical center (the environment). 
Preventing and treating CDI is dependent upon understanding the components of epidemiology 
including pathogenicity, sporulation, transmission, and impact of the bacterial toxins on the 
gastrointestional tract will continue to be important factors in treating CDI, preventing associated 
complications, preventing transmission, and reducing disease recurrence. The order set 
contained treatment targeted at eliminating Clostridium difficile bacteria causing an infection 
based upon disease severity. The intent of the order set was to influence and guide clinicians to 
use evidence-based treatment. Identifying risk factors for the development of CDI assisted the 
clinicians in eliminating or reducing modifiable risks factors when feasible. For example, 
reducing or eliminating gastric acid suppression use. However, factors such as age could not be 
modified. Additionally, the order set prompted the utilization of enteric precautions. This 
intervention was aimed at reducing person-to person transmission through the use of protective 
wear (gowns and gloves), proper handwashing with soap and water, and dedicated equipment 
(disposable thermometer and stethoscope). Once enteric precautions were initiated, a sign was 
placed on the patient hospital door to alert persons entering the room of the guidelines to be 
followed before, during and after entry. The framework also helped to understand the effect of 
treatment on the host or outcomes such as cure, recurrence, and treatment failures. Although 
the framework provides a basic understanding of communicable diseases and interactions with 
the environment and host, it is not specific to CDI. Despite the applicability of the framework, it 
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was lacking generalizability as each infectious agent, host, and environment has unique 
features that cannot be accounted for by the epidemiological triangle.  
Evidence-Based Practice Framework 
The Iowa Model Revised: Evidence-Based Practice to Promote Excellence in Health 
Care was the evidence-based practice framework used to guide the development of this study. 
The framework was an effective model as its steps of the algorithm correlated with the process 
necessary to implement a practice change at the clinical agency. The model was modified as 
several obstacles during the change implementation required revision or involvement of other 
clinical agency stakeholders that were not previously identified. The clinical agency also 
required order set revisions to comply with institutional policies. An example was the inclusion of 
fidaxomicin on the initially proposed order set under disease recurrence. The request to include 
it on the order set was declined due to clinical agency policy against the use of non-formulary 
medications, such as fidaxomicin, on order sets. A suggestion was made to add a statement to 
the order set advising the users of the non-formulary medication status and requirement for an 
infectious disease consultation to order this particular medication. Unfortunately, making this 
addition to the order set was rejected. It was felt that this would potentially increase unwarranted 
use of this costly medication. It is unlikely that modifications to the model would be required for 
future use as they were primarily necessary due to the investigator’s lack of familiarity of the 
clinical agency process to implement practice changes. However, the model can easily be 
adapted to meet the need of the user.  
Strengths and weaknesses 
The study incorporated current evidence from literature and included a multidisciplinary 
team for order set development, content review, and implementation. The order set is an easily 
accessible, disease-severity based treatment tool for clinicians.  Although previous studies have 
implemented treatment stewardships, use of an order set was a novel approach to CDI 
treatment at the clinical agency. As far as it is known, an order set specifically directed at CDI 
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treatment had not previously been developed or implemented at the clinical agency. Despite the 
availability of the order set, only 13% of clinicians utilized the order set. This could be potentially 
explained by several factors including: lack of order set awareness, clinician confidence in 
personal CDI treatment knowledge, avoidance due to belief that order sets do not allow for 
treatment individualization, lack of awareness of clinical agency treatment variability among 
clinicians, and non-mandatory use status. Although multimodal education was used prior to 
order set release, the education period was limited to two weeks prior to the start of the 
implementation period due to delays in final approval of the order set.  A longer education 
period prior to the order set release may have proven beneficial as it would allowed for more 
opportunities to reach out to more clinicians and medical students. The multimodal educational 
approach included: email notifications to department chiefs and chief residents, medical 
newsletter notification, information technology newsletter notification, posters, and face-to-face 
education. In retrospect, sending out email notifications to all clinicians and medical students 
would have been a better choice to ensure more clinicians and medical students received 
personal notification of the order set release. In person in-services or computer-based 
presentations prior to the order set release may have been useful for increasing clinician 
awareness to the increased number of cases of CDI at the academic medical center over the 
last three years, clinician treatment variability, upcoming financial penalty changes for hospital 
acquired CDI, and the possible association between guideline non-adherent treatment and poor 
patient outcomes. Short questionnaires could have also been used to test clinician knowledge of 
current CDI treatment guidelines and assist in the recognition of any knowledge deficits related 
to CDI treatment. Initially a computer-based message alerting clinicians of a positive stool study 
and a reminder to utilize the order set was suggested. Permission to implement such a 
message was declined to due to concern about alert fatigue.  
Another limitation may have included avoidance of order set use among some clinicians 
as they may feel it fails to address the need to individualize treatment in special cases. This 
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issue was brought forth by one of the key stakeholders. However, as with every order set at the 
clinical agency a written disclaimer states that the recommendations in the order set serve as a 
guide and are not to replace clinical judgement. Additionally, the orders could be easily modified 
by clinicians. For example, a longer treatment period can be changed to meet the needs of 
individualize patients. One of the above mentioned studies successfully implemented a policy 
change that directed clinicians to utilize guidelines for treatment. The study demonstrated 
positive patient outcomes associated with guideline adherence. Given the initial stakeholder 
resistance to voluntary utilization of a guideline-based order set, significant resistance would 
probably make a mandatory policy change unlikely. 
Generalizability to patients outside of the clinical agency was also a possible limitation 
as the patient population at the academic medical center have numerous risk factors for CDI 
(i.e. immunosuppression, antimicrobial use, recent health care facility stay, gastric acid 
suppression, and history of CDI) that may not be seen to the same extent in smaller hospitals.  
Despite the identified limitations, this study enforced there are improvements to be made 
both in the treatment and prevention of CDI. This study has brought attention to the need for the 
clinical agency and stakeholders to strengthen efforts to improvement strategies directed at both 
prevention and treatment. 
Implications for the future 
Practice. In response to the growing number of HAI, a government-based program was 
established to reduce payments to hospitals with poor HAI prevention performance. Currently, 
CAUTI, CLABSI, and surgical site infections (colon and abdominal hysterectomy) are quality 
measures tracked under the program. In 2017, MRSA and CDI will be added to the list of quality 
measures. Health care systems that fail to respond to the growing number of CDI will be at risk 
for financial penalties and reduced reimbursement. Reducing risk factors associated with CDI 
has proven challenging. Those risk factors include immunosuppression, antimicrobial therapy, 
recent health care facility stay, gastric acid suppression, and history of CDI. Although the 
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purpose of this study focused on treatment, implementing preventive measures will also be 
instrumental in reducing the incidence of CDI. Treatment goals need to be aimed at using 
evidence-based practices to successfully treat CDI and reduce future recurrence. Post-
implementation data indicated few clinicians are using recommended treatment for CDI, 
especially for severe and severe complicated disease. These more severe cases may develop 
potentially fatal complications, such as pseudomembranous colitis or sepsis. Dissemination of 
the findings can be utilized to encourage incorporation of current evidence into clinical practice. 
It has also been demonstrated that preventive efforts such as reducing modifiable risk factors 
(i.e. gastric acid suppression and antimicrobial therapy) may potentially reduce disease 
recurrence. Implementing a treatment policy as with one of the previously mentioned studies 
would likely improve clinician guideline adherence. The findings will be disseminated at the 
clinical agency to determine if the set will be extended beyond the pilot study period. It will also 
be suggested for the clinical agency to develop a multidisciplinary team aimed at both treatment 
and prevention strategies. 
Theory. Utilization of theoretical framework, such as the Iowa Model, will prove 
invaluable for future efforts in the prevention and treatment of CDI. The model offers a 
systematic approach to identifying problems, prioritizing problems, searching for and 
synthesizing best evidence in literature, developing and implementing changes, evaluating 
implemented practice change, and determining if the proposed change will be adopted into 
practice. The model has been revised twice times since the original model was released. The 
changes have been in response to changes in the health care industry and used feedback. This 
demonstrates the responsiveness and adaptability to the dynamic nature of health care. It is 
likely the model will continued to be revised in response to changes in healthcare. 
Research. Future longitudinal, multicenter studies should be conducted to determine the 
long-term effect of treatment stewardships on clinical cure rates, 30-day disease recurrence, 
and 30-day readmission rates for CDI. Future studies should also be designed to account for 
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confounding factors that may impact patient outcomes. Future studies should also consider 
follow-up patient phone calls to determine a more accurate account of disease recurrences and 
readmissions. As previously mentioned, there were patients transferred from other hospitals for 
their treatment. Post discharge care may have been at local health care systems limiting an 
accurate accounts of disease recurrence and 30-day readmissions for CDI.  
If the order set is adopted into practice at the clinical agency, efforts must be made to 
conduct interval literature reviews to identify any new evidence related to CDI treatment and 
determine if it should be incorporated in order to reflect best practice. 
Education. Although patient education was not an intended focus of this study, only 
20% of patients in both the pre- and post-implementation groups received CDI-specific 
discharge instructions. In the post-implementation group, the failure to provide CDI specific 
instructions did not appear to have a negative effect on 30-day disease recurrence (22.2% 
received instructions vs 5.6% did not receive instructions, p = 0.173) or 30-day readmission 
rates (22.2% received instructions vs 8.3% did not receive instructions, p = 0.258). Failure to 
provide CDI specific discharge instructions (i.e. risk factors, transmission, and hand washing) to 
patients and their families may contribute to disease recurrence and transmission to others 
although this study did not demonstrate any negative effect on patient outcomes. An 
explanation for this finding may have been clinician failure to document CDI specific instructions 
provided at the time of discharge. Additionally, clinician education regarding CDI treatment must 
be continued, as well as the potential impact of inappropriate treatment of CDI. This includes 
complications associated with CDI and the potential financial impact on healthcare systems for 
hospital-acquired CDI. 
The study has showed a significant number of patients did not receive guideline 
adherent treatment. The long term implications on patient outcomes has yet to be fully 
demonstrated. Treating patients with a mild to moderate disease may lead to unnecessary 
utilization of vancomycin and increased risk for development of vancomycin resistant 
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enterococcus (VRE). Unwarranted use of vancomycin also creates an unnecessary expense as 
the cost is higher than metronidazole. Additionally, patients with severe or severe/complicated 
disease may develop CDI related complications (i.e. pseudomembranous colitis) due to failure 
to appropriately treat with a combination of metronidazole and an appropriate dose of 
vancomycin. Inclusion of fidaxomicin for recurrent disease may have also reduced the number 
of recurrences. Despite the cost of fidaxomicin and its non-formulary status at the clinical 
agency, utilization may have decreased recurrence and proven less costly than the expense 
and potential complications associated with disease recurrence, as well as the possible need for 
the potentially more costly treatment option, fecal microbiota transplant.  
Conclusions 
CDI is a continued health care issue that can result in a number of disease-associated 
complications. Successfully reducing the incidence of CDI must include interventions aimed at 
both prevention and treatment. This study has demonstrated there is still work to be done in 
making improvements to both preventing and treating this growing problem. In addition to the 
possible physical complications associated with CDI, there may also be a significant financial 
impact on healthcare systems. It has previously been demonstrated that CDI has been 
associated with increased length of stay (LOS). In addition, impending reimbursement changes 
for HAI may have a potentially devastating effect on health care systems as CDI will be added 
the list of HAI that will result in potential financial penalties beginning in 2017. Efforts aimed at 
disease prevention, such as enteric isolation precautions for suspected and confirmed CDI 
cases, responsible use of antibiotic and gastric acid suppression, and patient education should 
also be encouraged. Failure to incorporate evidence-based practice for CDI treatment and 
prevention may have potentially devastating physical and financial consequences. This study 
also demonstrated doctoral-prepared advanced practice nurses have the ability and 
commitment to develop, implement, and evaluate clinical practice changes to improve patient 
outcomes through incorporation of evidence-based practice. References 
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ACRONYM LIST 
AAD: antibiotic-associated diarrhea 
ACA: Affordable Care Act 
ACG: American College of Gastroenterology 
AHRQ: Agency for Healthcare Research and Quality  
CASP: Critical Appraisal Skills Programme  
CDC: Centers for Disease Control and Prevention 
CDI: Clostridium difficile infection 
CINAHL: Cumulative Index to Nursing and Allied Health 
CMS: Centers for Medicare and Medicaid Services 
EBP: Evidence-Based Practice 
HAC: hospital acquired conditions 
HAI: hospital acquired infections 
HRRP: Hospital Readmission Reduction Program 
IOM: Institute of Medicine  
JBI: The Joanna Briggs Search Institute 
NCBI: Medline/National Center for Biotechnology Information (NCBI) 
PI: principal investigator 
SHEA/IDSA: Society of Hospital Epidemiologists of America/ Infectious Disease Society of      
     America 
VRE: vancomycin resistance enterococcus 
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Appendix A. Clostridium difficile Infection Order Set 
 
 
Date Time Physician Orders 
  Labs        
 
 serum creatinine daily collection routine, results routine x 2 days 
 serum albumin daily collection routine, results routine x 2 days 
 CBC with differential daily collection routine, results routine x 2 days 
 venous lactate  x 1  collection routine, results routine 
 
  Medications 
 
**Discontinue inciting antibiotics if possible 
**Discontinue or limit gastric suppressant medications (i.e. H2 blockers, PPIs) if 
possible 
**Duration can be modified by the clinician to individualize treatment  
 
Mild to Moderate Disease  
**WBC count less than  15,000  OR serum creatinine less than 1.5 times baseline 
AND absence of severe disease criteria 
 
 metroNIDAZOLE 500 mg Q8H for 10 days 
 PO (DEF)    Feeding Tube  
  
**For ALLERGY / intolerance to metroNIDAZOLE OR   
   No clinical improvement in 5-7 days on metroNIDAZOLE OR  
   Pregnant / breastfeeding OR  
   History of inflammatory bowel disease 
 
 vancomycin 125 mg Q6H, oral susp. for 10 days 
 PO (DEF)    Feeding Tube  
 
   
Severe Disease  
**Serum albumin less than 3 gm/dL AND one of the following: serum creatinine 
greater than 1.5 times baseline OR abdominal tenderness OR WBC greater than or 
equal to 15,000 
 
 vancomycin 125 mg orally Q6H for 10 days 
 PO (DEF)    Feeding Tube  
 
 
 
 
 
 
 
Clostridium difficile Infection 
       The person initiating entry should write legibly, date the form (using Mo / Day / Yr), enter time, sign,   
and indicate their title. 
Until signed, these are for general information and reference only.  They should not be relied on as advice for a particular patient or situation or as a 
substitute for the independent professional judgment of the physician. 
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Date Time Physician Orders 
Severe Complicated Disease 
 
**Intensive care unit admission for Clostridium difficile infection  OR hypotension with or 
without required vasopressors  OR fever greater than or equal to 38.5  OR ileus  OR 
megacolon  OR significant abdominal distention  OR mental status changes  OR WBC 
greater than or equal to 35,000  OR WBC less than or equal to 2,000  OR serum lactate 
greater than 2.2  OR evidence of end organ damage 
 
 vancomycin 500 mg Q6H for 10 days 
 PO (DEF)    Feeding Tube  
       AND 
 metroNIDAZOLE 500 mg IVPB Q8H for 10 days 
 
       AND 
 
*IF ILEUS is present or suspected OR if there is a history of Hartman’s pouch, 
ileostomy, or colon diversion.  
 
 vancomycin 500 mg in 500 mL 0.9% sodium chloride per rectum Q6H  
 
**Consider surgical consultation  for all severe complicated cases 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Recurrent Infection Treatment 
**Recurrence defined as an episode that occurs 8 weeks after a previous episode that 
involved resolution of symptoms 
 
First Recurrence of mild to moderate disease: Repeat initial regimen 
  
 metroNIDAZOLE 500 mg orally Q8H for 10 days 
 PO (DEF)    Feeding Tube 
       OR  
 vancomycin 125 mg Q6H for 10 days 
 
 PO (DEF)    Feeding Tube  
 
First Recurrence of severe or severe complicated disease 
 
 vancomycin 125 mg Q6H for 10 days 
 PO (DEF)    Feeding Tube  
 
Second Recurrence 
 
 vancomycin 125 mg Q6H for 10 days,  
 PO (DEF)    Feeding Tube  
THEN 
 vancomycin 125 mg Q12H for 7 days 
 PO (DEF)    Feeding Tube  
THEN 
 vancomycin 125 mg orally Q24H for 7 days 
 PO (DEF)    Feeding Tube  
THEN 
*May choose a duration of up to 2-8 weeks* 
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Date Time Physician Orders 
 vancomycin 125 mg Q48H for 2 weeks 
 PO (DEF)    Feeding Tube  
  
***For reoccurrence and treatment failure CONSIDER infectious disease and GI 
consultation  
       
Third and Subsequent recurrences  
 
***consider fecal microbiota transplant               
 
  Consults 
Note: Ordering provider must call service for consult* 
 medical service consult : gastroenterology  
 medical service consult : surgical  
 medical service consult : infectious disease  
 Social work consult – if vancomycin therapy needed upon discharge 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
